Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration

With the advent of effective antiretroviral treatment, the life expectancy for people with HIV is now approaching that seen in the general population. Consequently, the relative importance of other traditionally non-AIDS-related morbidities has increased. We investigated trends over time in all-caus...

Full description

Saved in:

Bibliographic Details
Published in:	The Lancet (British edition) Vol. 384; no. 9939; pp. 241 - 248
Main Authors:	Smith, Colette J, Ryom, Lene, Weber, Rainer, Morlat, Philippe, Pradier, Christian, Reiss, Peter, Kowalska, Justyna D, de Wit, Stephane, Law, Matthew, el Sadr, Wafaa, Kirk, Ole, Friis-Moller, Nina, Monforte, Antonella d'Arminio, Phillips, Andrew N, Sabin, Caroline A, Lundgren, Jens D
Format:	Journal Article
Language:	English
Published:	Kidlington Elsevier Ltd 19.07.2014 Elsevier Elsevier Limited
Subjects:	Acquired immune deficiency syndrome Acquired Immunodeficiency Syndrome - mortality Adult AIDS Antiretroviral agents Antiretroviral drugs Australia - epidemiology Biological and medical sciences Cardiovascular diseases Cause of Death - trends Data collection Europe - epidemiology Female General aspects HIV HIV Infections - mortality Human immunodeficiency virus Human viral diseases Humans Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Infectious diseases Internal Medicine Life expectancy Liver Male Medical sciences Middle Aged Mortality Poisson Distribution Public health Risk Factors United States - epidemiology Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Australia United States Europe Immunopathology Mortality Retroviridae Trend AIDS Immune deficiency Lentivirus Infection Virus Medicine Etiology Viral disease Cooperation Cause Death Human immunodeficiency virus Causality 1999
ISSN:	0140-6736, 1474-547X, 1474-547X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	With the advent of effective antiretroviral treatment, the life expectancy for people with HIV is now approaching that seen in the general population. Consequently, the relative importance of other traditionally non-AIDS-related morbidities has increased. We investigated trends over time in all-cause mortality and for specific causes of death in people with HIV from 1999 to 2011. Individuals from the Data collection on Adverse events of anti-HIV Drugs (D:A:D) study were followed up from March, 1999, until death, loss to follow-up, or Feb 1, 2011, whichever occurred first. The D:A:D study is a collaboration of 11 cohort studies following HIV-1-positive individuals receiving care at 212 clinics in Europe, USA, and Australia. All fatal events were centrally validated at the D:A:D coordinating centre using coding causes of death in HIV (CoDe) methodology. We calculated relative rates using Poisson regression. 3909 of the 49 731 D:A:D study participants died during the 308 719 person-years of follow-up (crude incidence mortality rate, 12·7 per 1000 person-years [95% CI 12·3–13·1]). Leading underlying causes were: AIDS-related (1123 [29%] deaths), non-AIDS-defining cancers (590 [15%] deaths), liver disease (515 [13%] deaths), and cardiovascular disease (436 [11%] deaths). Rates of all-cause death per 1000 person-years decreased from 17·5 in 1999–2000 to 9·1 in 2009–11; we saw similar decreases in death rates per 1000 person-years over the same period for AIDS-related deaths (5·9 to 2·0), deaths from liver disease (2·7 to 0·9), and cardiovascular disease deaths (1·8 to 0·9). However, non-AIDS cancers increased slightly from 1·6 per 1000 person-years in 1999–2000 to 2·1 in 2009–11 (p=0·58). After adjustment for factors that changed over time, including CD4 cell count, we detected no decreases in AIDS-related death rates (relative rate for 2009–11 vs 1999–2000: 0·92 [0·70–1·22]). However, all-cause (0·72 [0·61–0·83]), liver disease (0·48 [0·32–0·74]), and cardiovascular disease (0·33 [0·20–0·53) death rates still decreased over time. The percentage of all deaths that were AIDS-related (87/256 [34%] in 1999–2000 and 141/627 [22%] in 2009–11) and liver-related (40/256 [16%] in 1999–2000 and 64/627 [10%] in 2009–11) decreased over time, whereas non-AIDS cancers increased (24/256 [9%] in 1999–2000 to 142/627 [23%] in 2009–11). Recent reductions in rates of AIDS-related deaths are linked with continued improvement in CD4 cell count. We hypothesise that the substantially reduced rates of liver disease and cardiovascular disease deaths over time could be explained by improved use of non-HIV-specific preventive interventions. Non-AIDS cancer is now the leading non-AIDS cause and without any evidence of improvement. Oversight Committee for the Evaluation of Metabolic Complications of HAART, with representatives from academia, patient community, US Food and Drug Administration, European Medicines Agency and consortium of AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, ViiV Healthcare, Merck, Pfizer, F Hoffmann-La Roche, and Janssen Pharmaceuticals.
AbstractList	With the advent of effective antiretroviral treatment, the life expectancy for people with HIV is now approaching that seen in the general population. Consequently, the relative importance of other traditionally non-AIDS-related morbidities has increased. We investigated trends over time in all-cause mortality and for specific causes of death in people with HIV from 1999 to 2011.BACKGROUNDWith the advent of effective antiretroviral treatment, the life expectancy for people with HIV is now approaching that seen in the general population. Consequently, the relative importance of other traditionally non-AIDS-related morbidities has increased. We investigated trends over time in all-cause mortality and for specific causes of death in people with HIV from 1999 to 2011.Individuals from the Data collection on Adverse events of anti-HIV Drugs (D:A:D) study were followed up from March, 1999, until death, loss to follow-up, or Feb 1, 2011, whichever occurred first. The D:A:D study is a collaboration of 11 cohort studies following HIV-1-positive individuals receiving care at 212 clinics in Europe, USA, and Australia. All fatal events were centrally validated at the D:A:D coordinating centre using coding causes of death in HIV (CoDe) methodology. We calculated relative rates using Poisson regression.METHODSIndividuals from the Data collection on Adverse events of anti-HIV Drugs (D:A:D) study were followed up from March, 1999, until death, loss to follow-up, or Feb 1, 2011, whichever occurred first. The D:A:D study is a collaboration of 11 cohort studies following HIV-1-positive individuals receiving care at 212 clinics in Europe, USA, and Australia. All fatal events were centrally validated at the D:A:D coordinating centre using coding causes of death in HIV (CoDe) methodology. We calculated relative rates using Poisson regression.3909 of the 49,731 D:A:D study participants died during the 308,719 person-years of follow-up (crude incidence mortality rate, 12.7 per 1000 person-years [95% CI 12.3-13.1]). Leading underlying causes were: AIDS-related (1123 [29%] deaths), non-AIDS-defining cancers (590 [15%] deaths), liver disease (515 [13%] deaths), and cardiovascular disease (436 [11%] deaths). Rates of all-cause death per 1000 person-years decreased from 17.5 in 1999-2000 to 9.1 in 2009-11; we saw similar decreases in death rates per 1000 person-years over the same period for AIDS-related deaths (5.9 to 2.0), deaths from liver disease (2.7 to 0.9), and cardiovascular disease deaths (1.8 to 0.9). However, non-AIDS cancers increased slightly from 1.6 per 1000 person-years in 1999-2000 to 2.1 in 2009-11 (p=0.58). After adjustment for factors that changed over time, including CD4 cell count, we detected no decreases in AIDS-related death rates (relative rate for 2009-11 vs 1999-2000: 0.92 [0.70-1.22]). However, all-cause (0.72 [0.61-0.83]), liver disease (0.48 [0.32-0.74]), and cardiovascular disease (0.33 [0.20-0.53) death rates still decreased over time. The percentage of all deaths that were AIDS-related (87/256 [34%] in 1999-2000 and 141/627 [22%] in 2009-11) and liver-related (40/256 [16%] in 1999-2000 and 64/627 [10%] in 2009-11) decreased over time, whereas non-AIDS cancers increased (24/256 [9%] in 1999-2000 to 142/627 [23%] in 2009-11).FINDINGS3909 of the 49,731 D:A:D study participants died during the 308,719 person-years of follow-up (crude incidence mortality rate, 12.7 per 1000 person-years [95% CI 12.3-13.1]). Leading underlying causes were: AIDS-related (1123 [29%] deaths), non-AIDS-defining cancers (590 [15%] deaths), liver disease (515 [13%] deaths), and cardiovascular disease (436 [11%] deaths). Rates of all-cause death per 1000 person-years decreased from 17.5 in 1999-2000 to 9.1 in 2009-11; we saw similar decreases in death rates per 1000 person-years over the same period for AIDS-related deaths (5.9 to 2.0), deaths from liver disease (2.7 to 0.9), and cardiovascular disease deaths (1.8 to 0.9). However, non-AIDS cancers increased slightly from 1.6 per 1000 person-years in 1999-2000 to 2.1 in 2009-11 (p=0.58). After adjustment for factors that changed over time, including CD4 cell count, we detected no decreases in AIDS-related death rates (relative rate for 2009-11 vs 1999-2000: 0.92 [0.70-1.22]). However, all-cause (0.72 [0.61-0.83]), liver disease (0.48 [0.32-0.74]), and cardiovascular disease (0.33 [0.20-0.53) death rates still decreased over time. The percentage of all deaths that were AIDS-related (87/256 [34%] in 1999-2000 and 141/627 [22%] in 2009-11) and liver-related (40/256 [16%] in 1999-2000 and 64/627 [10%] in 2009-11) decreased over time, whereas non-AIDS cancers increased (24/256 [9%] in 1999-2000 to 142/627 [23%] in 2009-11).Recent reductions in rates of AIDS-related deaths are linked with continued improvement in CD4 cell count. We hypothesise that the substantially reduced rates of liver disease and cardiovascular disease deaths over time could be explained by improved use of non-HIV-specific preventive interventions. Non-AIDS cancer is now the leading non-AIDS cause and without any evidence of improvement.INTERPRETATIONRecent reductions in rates of AIDS-related deaths are linked with continued improvement in CD4 cell count. We hypothesise that the substantially reduced rates of liver disease and cardiovascular disease deaths over time could be explained by improved use of non-HIV-specific preventive interventions. Non-AIDS cancer is now the leading non-AIDS cause and without any evidence of improvement.Oversight Committee for the Evaluation of Metabolic Complications of HAART, with representatives from academia, patient community, US Food and Drug Administration, European Medicines Agency and consortium of AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, ViiV Healthcare, Merck, Pfizer, F Hoffmann-La Roche, and Janssen Pharmaceuticals.FUNDINGOversight Committee for the Evaluation of Metabolic Complications of HAART, with representatives from academia, patient community, US Food and Drug Administration, European Medicines Agency and consortium of AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, ViiV Healthcare, Merck, Pfizer, F Hoffmann-La Roche, and Janssen Pharmaceuticals. With the advent of effective antiretroviral treatment, the life expectancy for people with HIV is now approaching that seen in the general population. Consequently, the relative importance of other traditionally non-AIDS-related morbidities has increased. We investigated trends over time in all-cause mortality and for specific causes of death in people with HIV from 1999 to 2011. Individuals from the Data collection on Adverse events of anti-HIV Drugs (D:A:D) study were followed up from March, 1999, until death, loss to follow-up, or Feb 1, 2011, whichever occurred first. The D:A:D study is a collaboration of 11 cohort studies following HIV-1-positive individuals receiving care at 212 clinics in Europe, USA, and Australia. All fatal events were centrally validated at the D:A:D coordinating centre using coding causes of death in HIV (CoDe) methodology. We calculated relative rates using Poisson regression. 3909 of the 49,731 D:A:D study participants died during the 308,719 person-years of follow-up (crude incidence mortality rate, 12.7 per 1000 person-years [95% CI 12.3-13.1]). Leading underlying causes were: AIDS-related (1123 [29%] deaths), non-AIDS-defining cancers (590 [15%] deaths), liver disease (515 [13%] deaths), and cardiovascular disease (436 [11%] deaths). Rates of all-cause death per 1000 person-years decreased from 17.5 in 1999-2000 to 9.1 in 2009-11; we saw similar decreases in death rates per 1000 person-years over the same period for AIDS-related deaths (5.9 to 2.0), deaths from liver disease (2.7 to 0.9), and cardiovascular disease deaths (1.8 to 0.9). However, non-AIDS cancers increased slightly from 1.6 per 1000 person-years in 1999-2000 to 2.1 in 2009-11 (p=0.58). After adjustment for factors that changed over time, including CD4 cell count, we detected no decreases in AIDS-related death rates (relative rate for 2009-11 vs 1999-2000: 0.92 [0.70-1.22]). However, all-cause (0.72 [0.61-0.83]), liver disease (0.48 [0.32-0.74]), and cardiovascular disease (0.33 [0.20-0.53) death rates still decreased over time. The percentage of all deaths that were AIDS-related (87/256 [34%] in 1999-2000 and 141/627 [22%] in 2009-11) and liver-related (40/256 [16%] in 1999-2000 and 64/627 [10%] in 2009-11) decreased over time, whereas non-AIDS cancers increased (24/256 [9%] in 1999-2000 to 142/627 [23%] in 2009-11). Recent reductions in rates of AIDS-related deaths are linked with continued improvement in CD4 cell count. We hypothesise that the substantially reduced rates of liver disease and cardiovascular disease deaths over time could be explained by improved use of non-HIV-specific preventive interventions. Non-AIDS cancer is now the leading non-AIDS cause and without any evidence of improvement. Oversight Committee for the Evaluation of Metabolic Complications of HAART, with representatives from academia, patient community, US Food and Drug Administration, European Medicines Agency and consortium of AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, ViiV Healthcare, Merck, Pfizer, F Hoffmann-La Roche, and Janssen Pharmaceuticals. With the advent of effective antiretroviral treatment, the life expectancy for people with HIV is now approaching that seen in the general population. Consequently, the relative importance of other traditionally non-AIDS-related morbidities has increased. We investigated trends over time in all-cause mortality and for specific causes of death in people with HIV from 1999 to 2011. Individuals from the Data collection on Adverse events of anti-HIV Drugs (D:A:D) study were followed up from March, 1999, until death, loss to follow-up, or Feb 1, 2011, whichever occurred first. The D:A:D study is a collaboration of 11 cohort studies following HIV-1-positive individuals receiving care at 212 clinics in Europe, USA, and Australia. All fatal events were centrally validated at the D:A:D coordinating centre using coding causes of death in HIV (CoDe) methodology. We calculated relative rates using Poisson regression. 3909 of the 49 731 D:A:D study participants died during the 308 719 person-years of follow-up (crude incidence mortality rate, 12·7 per 1000 person-years [95% CI 12·3–13·1]). Leading underlying causes were: AIDS-related (1123 [29%] deaths), non-AIDS-defining cancers (590 [15%] deaths), liver disease (515 [13%] deaths), and cardiovascular disease (436 [11%] deaths). Rates of all-cause death per 1000 person-years decreased from 17·5 in 1999–2000 to 9·1 in 2009–11; we saw similar decreases in death rates per 1000 person-years over the same period for AIDS-related deaths (5·9 to 2·0), deaths from liver disease (2·7 to 0·9), and cardiovascular disease deaths (1·8 to 0·9). However, non-AIDS cancers increased slightly from 1·6 per 1000 person-years in 1999–2000 to 2·1 in 2009–11 (p=0·58). After adjustment for factors that changed over time, including CD4 cell count, we detected no decreases in AIDS-related death rates (relative rate for 2009–11 vs 1999–2000: 0·92 [0·70–1·22]). However, all-cause (0·72 [0·61–0·83]), liver disease (0·48 [0·32–0·74]), and cardiovascular disease (0·33 [0·20–0·53) death rates still decreased over time. The percentage of all deaths that were AIDS-related (87/256 [34%] in 1999–2000 and 141/627 [22%] in 2009–11) and liver-related (40/256 [16%] in 1999–2000 and 64/627 [10%] in 2009–11) decreased over time, whereas non-AIDS cancers increased (24/256 [9%] in 1999–2000 to 142/627 [23%] in 2009–11). Recent reductions in rates of AIDS-related deaths are linked with continued improvement in CD4 cell count. We hypothesise that the substantially reduced rates of liver disease and cardiovascular disease deaths over time could be explained by improved use of non-HIV-specific preventive interventions. Non-AIDS cancer is now the leading non-AIDS cause and without any evidence of improvement. Oversight Committee for the Evaluation of Metabolic Complications of HAART, with representatives from academia, patient community, US Food and Drug Administration, European Medicines Agency and consortium of AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, ViiV Healthcare, Merck, Pfizer, F Hoffmann-La Roche, and Janssen Pharmaceuticals. Summary Background With the advent of effective antiretroviral treatment, the life expectancy for people with HIV is now approaching that seen in the general population. Consequently, the relative importance of other traditionally non-AIDS-related morbidities has increased. We investigated trends over time in all-cause mortality and for specific causes of death in people with HIV from 1999 to 2011. Methods Individuals from the Data collection on Adverse events of anti-HIV Drugs (D:A:D) study were followed up from March, 1999, until death, loss to follow-up, or Feb 1, 2011, whichever occurred first. The D:A:D study is a collaboration of 11 cohort studies following HIV-1-positive individuals receiving care at 212 clinics in Europe, USA, and Australia. All fatal events were centrally validated at the D:A:D coordinating centre using coding causes of death in HIV (CoDe) methodology. We calculated relative rates using Poisson regression. Findings 3909 of the 49 731 D:A:D study participants died during the 308 719 person-years of follow-up (crude incidence mortality rate, 12·7 per 1000 person-years [95% CI 12·3–13·1]). Leading underlying causes were: AIDS-related (1123 [29%] deaths), non-AIDS-defining cancers (590 [15%] deaths), liver disease (515 [13%] deaths), and cardiovascular disease (436 [11%] deaths). Rates of all-cause death per 1000 person-years decreased from 17·5 in 1999–2000 to 9·1 in 2009–11; we saw similar decreases in death rates per 1000 person-years over the same period for AIDS-related deaths (5·9 to 2·0), deaths from liver disease (2·7 to 0·9), and cardiovascular disease deaths (1·8 to 0·9). However, non-AIDS cancers increased slightly from 1·6 per 1000 person-years in 1999–2000 to 2·1 in 2009–11 (p=0·58). After adjustment for factors that changed over time, including CD4 cell count, we detected no decreases in AIDS-related death rates (relative rate for 2009–11 vs 1999–2000: 0·92 [0·70–1·22]). However, all-cause (0·72 [0·61–0·83]), liver disease (0·48 [0·32–0·74]), and cardiovascular disease (0·33 [0·20–0·53) death rates still decreased over time. The percentage of all deaths that were AIDS-related (87/256 [34%] in 1999–2000 and 141/627 [22%] in 2009–11) and liver-related (40/256 [16%] in 1999–2000 and 64/627 [10%] in 2009–11) decreased over time, whereas non-AIDS cancers increased (24/256 [9%] in 1999–2000 to 142/627 [23%] in 2009–11). Interpretation Recent reductions in rates of AIDS-related deaths are linked with continued improvement in CD4 cell count. We hypothesise that the substantially reduced rates of liver disease and cardiovascular disease deaths over time could be explained by improved use of non-HIV-specific preventive interventions. Non-AIDS cancer is now the leading non-AIDS cause and without any evidence of improvement. Funding Oversight Committee for the Evaluation of Metabolic Complications of HAART, with representatives from academia, patient community, US Food and Drug Administration, European Medicines Agency and consortium of AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, ViiV Healthcare, Merck, Pfizer, F Hoffmann-La Roche, and Janssen Pharmaceuticals. With the advent of effective antiretroviral treatment, the life expectancy for people with HIV is now approaching that seen in the general population. Consequently, the relative importance of other traditionally non-AIDS-related morbidities has increased. We investigated trends over time in all-cause mortality and for specific causes of death in people with HIV from 1999 to 2011. Methods Individuals from the Data collection on Adverse events of anti-HIV Drugs (D:A:D) study were followed up from March, 1999, until death, loss to follow-up, or Feb 1, 2011, whichever occurred first. The D:A:D study is a collaboration of 11 cohort studies following HIV-1-positive individuals receiving care at 212 clinics in Europe, USA, and Australia. All fatal events were centrally validated at the D:A:D coordinating centre using coding causes of death in HIV (CoDe) methodology. We calculated relative rates using Poisson regression. Findings 3909 of the 49 731 D:A:D study participants died during the 308 719 person-years of follow-up (crude incidence mortality rate, 12·7 per 1000 person-years [95% CI 12·3-13·1]). Leading underlying causes were: AIDS-related (1123 [29%] deaths), non-AIDS-defining cancers (590 [15%] deaths), liver disease (515 [13%] deaths), and cardiovascular disease (436 [11%] deaths). Rates of all-cause death per 1000 person-years decreased from 17·5 in 1999-2000 to 9·1 in 2009-11; we saw similar decreases in death rates per 1000 person-years over the same period for AIDS-related deaths (5·9 to 2·0), deaths from liver disease (2·7 to 0·9), and cardiovascular disease deaths (1·8 to 0·9). However, non-AIDS cancers increased slightly from 1·6 per 1000 person-years in 1999-2000 to 2·1 in 2009-11 (p=0·58). After adjustment for factors that changed over time, including CD4 cell count, we detected no decreases in AIDS-related death rates (relative rate for 2009-11vs1999-2000: 0·92 [0·70-1·22]). However, all-cause (0·72 [0·61-0·83]), liver disease (0·48 [0·32-0·74]), and cardiovascular disease (0·33 [0·20-0·53) death rates still decreased over time. The percentage of all deaths that were AIDS-related (87/256 [34%] in 1999-2000 and 141/627 [22%] in 2009-11) and liver-related (40/256 [16%] in 1999-2000 and 64/627 [10%] in 2009-11) decreased over time, whereas non-AIDS cancers increased (24/256 [9%] in 1999-2000 to 142/627 [23%] in 2009-11). Interpretation Recent reductions in rates of AIDS-related deaths are linked with continued improvement in CD4 cell count. We hypothesise that the substantially reduced rates of liver disease and cardiovascular disease deaths over time could be explained by improved use of non-HIV-specific preventive interventions. Non-AIDS cancer is now the leading non-AIDS cause and without any evidence of improvement. Funding Oversight Committee for the Evaluation of Metabolic Complications of HAART, with representatives from academia, patient community, US Food and Drug Administration, European Medicines Agency and consortium of AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, ViiV Healthcare, Merck, Pfizer, F Hoffmann-La Roche, and Janssen Pharmaceuticals.
Author	Friis-Moller, Nina Smith, Colette J Reiss, Peter Phillips, Andrew N Lundgren, Jens D Ryom, Lene Pradier, Christian el Sadr, Wafaa Kowalska, Justyna D de Wit, Stephane Monforte, Antonella d'Arminio Weber, Rainer Morlat, Philippe Kirk, Ole Sabin, Caroline A Law, Matthew
Author_xml	– sequence: 1 givenname: Colette J surname: Smith fullname: Smith, Colette J email: c.smith@ucl.ac.uk organization: Research Department of Infection and Population Health, University College London, London, UK – sequence: 2 givenname: Lene surname: Ryom fullname: Ryom, Lene organization: CHIP, Department of Infectious Diseases , Rigshospitalet, University of Copenhagen, Denmark – sequence: 3 givenname: Rainer surname: Weber fullname: Weber, Rainer organization: Division of Infectious Diseases, University Hospital Zurich, University of Zurich, Zurich Switzerland – sequence: 4 givenname: Philippe surname: Morlat fullname: Morlat, Philippe organization: Service de Medecine Intern et Maladies Infectieuses, CHU de Bordeaux, Universite Bordeaux Segalen, Bordeaux, France – sequence: 5 givenname: Christian surname: Pradier fullname: Pradier, Christian organization: Department of Public Health, Nice University Hospital, Nice, France – sequence: 6 givenname: Peter surname: Reiss fullname: Reiss, Peter organization: Academic Medical Center, University of Amsterdam, and Stichting HIV Monitoring, Netherlands – sequence: 7 givenname: Justyna D surname: Kowalska fullname: Kowalska, Justyna D organization: Department of Adult's Infectious Diseases, Medical University of Warsaw, Poland – sequence: 8 givenname: Stephane surname: de Wit fullname: de Wit, Stephane organization: Department of Infectious Diseases, St Pierre University Hospital, Brussels, Belgium – sequence: 9 givenname: Matthew surname: Law fullname: Law, Matthew organization: The Kirby Institute, University of New South Wales, Sydney, NSW, Australia – sequence: 10 givenname: Wafaa surname: el Sadr fullname: el Sadr, Wafaa organization: Mailman School of Public Health, Columbia University, New York, USA – sequence: 11 givenname: Ole surname: Kirk fullname: Kirk, Ole organization: CHIP, Department of Infectious Diseases , Rigshospitalet, University of Copenhagen, Denmark – sequence: 12 givenname: Nina surname: Friis-Moller fullname: Friis-Moller, Nina organization: Department of Infectious Diseases, Odense University Hospital, Denmark – sequence: 13 givenname: Antonella d'Arminio surname: Monforte fullname: Monforte, Antonella d'Arminio organization: Department of Health Sciences, San Paolo University Hospital, Milan, Italy – sequence: 14 givenname: Andrew N surname: Phillips fullname: Phillips, Andrew N organization: Research Department of Infection and Population Health, University College London, London, UK – sequence: 15 givenname: Caroline A surname: Sabin fullname: Sabin, Caroline A organization: Research Department of Infection and Population Health, University College London, London, UK – sequence: 16 givenname: Jens D surname: Lundgren fullname: Lundgren, Jens D organization: CHIP, Department of Infectious Diseases , Rigshospitalet, University of Copenhagen, Denmark
BackLink	http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28691043$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/25042234$$D View this record in MEDLINE/PubMed
BookMark	eNqNkdFqFDEUhoNU7Lb6CEpAhO3FaDKTSSYrtpRWbaHghVW8C5nMGZs6k6zJjLJvb2Z3a2FB6lVI8p0vJ_85QHvOO0DoOSWvKaH8zWdCGcm4KPicsiNOOGFZ9QjNKBMsK5n4todmf5F9dBDjLSGEcVI-Qft5SVieF2yG3HUA10RsHR5dA6FbWfcdGz1GiNi3uAE93Ey3S_DLDvBvm7YXl19xG3yPqZQSDx7nhFI8P1-cLs6PFljjfuwGa_yNDwM2vut07YMerHdP0eNWdxGebddD9OXD--uzi-zq08fLs9OrzJRCDlmleS64MbVggtaVrIqGiIJoqCWvCpHLWotGN7rIWxANM7ItSTphrOVFTUxeHKL5xrsM_ucIcVC9jQZSJw78GBVNCZWMlrlI6Msd9NaPwaXuJqqsSsplkagXW2qse2jUMtheh5W6SzIBr7aAjkZ3bdDO2HjPVVxSwibR2w1ngo8xQKuMHdbZDEHbTlGipvmq9XzVNDxFmVrPV1WputypvnvgobqTTR2k0H9ZCCoaC85AYwOYQTXePmg43jGYzjqbvvoDVhDvM1MxV2QjmRyUrQ2T4N2_Bf_RwB9bk-Bq
CODEN	LANCAO
CitedBy_id	crossref_primary_10_1016_S0140_6736_17_32460_1 crossref_primary_10_1111_hiv_12241 crossref_primary_10_1111_hiv_13210 crossref_primary_10_1016_j_gheart_2014_08_006 crossref_primary_10_1080_03007995_2021_2003671 crossref_primary_10_1097_QAI_0000000000001271 crossref_primary_10_1089_aid_2019_0009 crossref_primary_10_1186_s12885_015_1099_y crossref_primary_10_1097_TP_0000000000001336 crossref_primary_10_1093_infdis_jiz367 crossref_primary_10_1016_j_canep_2015_09_002 crossref_primary_10_1155_2024_5590331 crossref_primary_10_1016_j_physbeh_2015_02_011 crossref_primary_10_1093_cid_ciz670 crossref_primary_10_1016_j_repc_2016_10_009 crossref_primary_10_1016_S2468_2667_16_30020_2 crossref_primary_10_3390_diagnostics12010014 crossref_primary_10_1097_QAI_0000000000001033 crossref_primary_10_1002_cpt_1393 crossref_primary_10_1097_QAD_0000000000001374 crossref_primary_10_1097_QAD_0000000000002583 crossref_primary_10_2147_HMER_S282662 crossref_primary_10_1097_QAI_0000000000003217 crossref_primary_10_1016_S0140_6736_14_60848_5 crossref_primary_10_1371_journal_pone_0246338 crossref_primary_10_1111_hiv_12231 crossref_primary_10_1097_COH_0000000000000320 crossref_primary_10_1097_JNC_0000000000000119 crossref_primary_10_1016_j_bjid_2017_02_003 crossref_primary_10_1371_journal_pone_0131353 crossref_primary_10_3389_frym_2022_912547 crossref_primary_10_1007_s15010_015_0745_2 crossref_primary_10_1089_aid_2015_0322 crossref_primary_10_1002_jmv_24826 crossref_primary_10_1016_j_drugalcdep_2020_108003 crossref_primary_10_1128_jvi_00588_22 crossref_primary_10_1097_QAD_0000000000001149 crossref_primary_10_1136_bmjopen_2018_022516 crossref_primary_10_1097_QAD_0000000000002233 crossref_primary_10_1371_journal_pone_0256164 crossref_primary_10_1097_COH_0000000000000327 crossref_primary_10_1097_QAD_0000000000002594 crossref_primary_10_1017_S0950268816003149 crossref_primary_10_1089_aid_2021_0091 crossref_primary_10_1089_aid_2019_0131 crossref_primary_10_1080_15284336_2016_1210719 crossref_primary_10_1093_jac_dkv473 crossref_primary_10_1016_j_repce_2016_10_019 crossref_primary_10_1016_j_ccl_2015_01_003 crossref_primary_10_1093_infdis_jiaa316 crossref_primary_10_4103_NJM_NJM_69_20 crossref_primary_10_1016_j_ijantimicag_2023_106897 crossref_primary_10_1093_cid_cix392 crossref_primary_10_1097_QAI_0000000000003318 crossref_primary_10_1097_COH_0000000000000418 crossref_primary_10_1097_COH_0000000000000417 crossref_primary_10_1002_cncr_30052 crossref_primary_10_1007_s10741_020_10048_8 crossref_primary_10_1016_j_eimce_2019_04_010 crossref_primary_10_1016_S2352_3018_15_00077_6 crossref_primary_10_1097_QAD_0000000000002002 crossref_primary_10_1097_QAI_0000000000002585 crossref_primary_10_1097_COH_0000000000000416 crossref_primary_10_1097_QAI_0000000000001014 crossref_primary_10_1097_COH_0000000000000410 crossref_primary_10_3389_fmed_2020_586390 crossref_primary_10_1097_COH_0000000000000411 crossref_primary_10_1002_cld_880 crossref_primary_10_1517_14656566_2015_973852 crossref_primary_10_1016_j_yasu_2017_03_005 crossref_primary_10_1093_infdis_jiy064 crossref_primary_10_1111_hiv_12497 crossref_primary_10_1016_j_idc_2018_02_004 crossref_primary_10_1177_2049936116681279 crossref_primary_10_1155_2020_8041616 crossref_primary_10_1080_14787210_2018_1471355 crossref_primary_10_1634_theoncologist_2016_0107 crossref_primary_10_1186_s12879_019_3851_4 crossref_primary_10_1111_jvh_13844 crossref_primary_10_1097_QAD_0000000000003467 crossref_primary_10_3389_fimmu_2023_1297378 crossref_primary_10_1097_QAD_0000000000002498 crossref_primary_10_1016_S2352_3018_22_00363_0 crossref_primary_10_1097_QAD_0000000000002255 crossref_primary_10_1002_ijc_35091 crossref_primary_10_1097_COH_0000000000000306 crossref_primary_10_3109_23744235_2015_1061204 crossref_primary_10_1097_COH_0000000000000305 crossref_primary_10_1371_journal_pone_0135602 crossref_primary_10_1097_COH_0000000000000420 crossref_primary_10_1080_09540121_2022_2074957 crossref_primary_10_1111_hiv_12368 crossref_primary_10_1007_s15010_017_1092_2 crossref_primary_10_1097_QAD_0000000000001170 crossref_primary_10_1186_s12879_016_2026_9 crossref_primary_10_1038_s41598_018_29739_2 crossref_primary_10_1016_j_rce_2017_07_011 crossref_primary_10_1097_QAI_0000000000001591 crossref_primary_10_1111_hiv_13250 crossref_primary_10_1186_s12889_015_1565_0 crossref_primary_10_1186_s13613_023_01171_4 crossref_primary_10_1007_s00432_023_05500_9 crossref_primary_10_1371_journal_pone_0211286 crossref_primary_10_1007_s12072_017_9788_z crossref_primary_10_1371_journal_pone_0177440 crossref_primary_10_1097_MOT_0000000000000199 crossref_primary_10_1136_bmjopen_2023_075673 crossref_primary_10_1097_QAD_0000000000003116 crossref_primary_10_1371_journal_pone_0179616 crossref_primary_10_2196_25660 crossref_primary_10_1111_hiv_13008 crossref_primary_10_1097_QAD_0000000000002387 crossref_primary_10_1093_ije_dyx075 crossref_primary_10_3390_ijerph18073437 crossref_primary_10_1007_s12328_016_0693_0 crossref_primary_10_1111_hiv_13246 crossref_primary_10_1200_GO_20_00153 crossref_primary_10_1097_QAD_0000000000003351 crossref_primary_10_1371_journal_pone_0228847 crossref_primary_10_1111_hiv_13127 crossref_primary_10_1097_EDE_0000000000001225 crossref_primary_10_1097_COH_0000000000000760 crossref_primary_10_1111_hiv_13245 crossref_primary_10_1155_2022_1298121 crossref_primary_10_3389_fimmu_2024_1362621 crossref_primary_10_1007_s10900_020_00844_6 crossref_primary_10_1177_2050312117725644 crossref_primary_10_1371_journal_pone_0223263 crossref_primary_10_1007_s15010_016_0880_4 crossref_primary_10_1007_s10096_018_3370_z crossref_primary_10_1089_apc_2020_29006_com crossref_primary_10_1016_S1470_2045_21_00137_6 crossref_primary_10_1097_QAD_0000000000002156 crossref_primary_10_1097_QAI_0000000000001342 crossref_primary_10_1186_s12879_015_0960_6 crossref_primary_10_1097_QAD_0000000000003240 crossref_primary_10_1111_jgh_15189 crossref_primary_10_1089_dna_2020_5444 crossref_primary_10_1016_j_jiac_2019_04_001 crossref_primary_10_1093_ntr_ntx145 crossref_primary_10_1097_PHH_0000000000001267 crossref_primary_10_1016_j_neulet_2021_135698 crossref_primary_10_1053_j_seminoncol_2019_09_007 crossref_primary_10_1161_JAHA_122_026473 crossref_primary_10_1177_0898264317724549 crossref_primary_10_1080_14787210_2021_1823217 crossref_primary_10_1111_hiv_13274 crossref_primary_10_1080_09540121_2022_2095334 crossref_primary_10_1371_journal_pone_0155753 crossref_primary_10_1111_hepr_13279 crossref_primary_10_1111_jvh_12707 crossref_primary_10_1093_geronb_gbab027 crossref_primary_10_3390_cancers15143640 crossref_primary_10_1186_s12879_017_2422_9 crossref_primary_10_1371_journal_pone_0225434 crossref_primary_10_1097_QAD_0000000000001076 crossref_primary_10_3748_wjg_v21_i43_12311 crossref_primary_10_1097_QAD_0000000000002161 crossref_primary_10_1155_2016_3420638 crossref_primary_10_1097_QAD_0000000000004235 crossref_primary_10_1097_TP_0000000000003107 crossref_primary_10_1016_j_bbih_2021_100342 crossref_primary_10_1016_j_chest_2019_08_002 crossref_primary_10_1177_0956462417724709 crossref_primary_10_3390_ijms241612871 crossref_primary_10_1016_j_jiph_2025_102654 crossref_primary_10_1097_QAI_0000000000002416 crossref_primary_10_1016_j_ahj_2018_12_016 crossref_primary_10_1016_j_cpcardiol_2025_103101 crossref_primary_10_1111_jvh_12836 crossref_primary_10_1177_09564624221089456 crossref_primary_10_1371_journal_pone_0176557 crossref_primary_10_1371_journal_pone_0278037 crossref_primary_10_4049_jimmunol_1402448 crossref_primary_10_3390_cells10051212 crossref_primary_10_1016_j_jiac_2021_02_003 crossref_primary_10_1038_s41598_019_41829_3 crossref_primary_10_1212_CPJ_0000000000200198 crossref_primary_10_3389_fneur_2021_593605 crossref_primary_10_1089_apc_2017_0063 crossref_primary_10_1007_s40495_018_0125_6 crossref_primary_10_1097_QAI_0000000000002898 crossref_primary_10_3748_wjg_v24_i7_767 crossref_primary_10_7759_cureus_85415 crossref_primary_10_1038_s41598_022_14170_5 crossref_primary_10_1186_s12879_016_1685_x crossref_primary_10_1002_hep_29071 crossref_primary_10_1016_j_virol_2015_06_029 crossref_primary_10_12688_f1000research_19585_1 crossref_primary_10_1016_j_cger_2016_02_010 crossref_primary_10_1016_j_drugalcdep_2016_11_006 crossref_primary_10_1089_aid_2021_0123 crossref_primary_10_1155_2018_6238978 crossref_primary_10_1136_bmjgast_2017_000166 crossref_primary_10_7326_M20_5226 crossref_primary_10_1007_s40256_020_00451_9 crossref_primary_10_1136_bmjopen_2018_025874 crossref_primary_10_1093_infdis_jiaa170 crossref_primary_10_1111_jvh_12447 crossref_primary_10_1007_s13546_015_1106_y crossref_primary_10_1093_jac_dkae244 crossref_primary_10_1177_0956462419866055 crossref_primary_10_1016_j_amjmed_2018_01_023 crossref_primary_10_1097_TP_0000000000001728 crossref_primary_10_3389_fimmu_2022_841314 crossref_primary_10_3390_v16020259 crossref_primary_10_1097_QAD_0000000000003281 crossref_primary_10_1136_jitc_2020_002097 crossref_primary_10_1136_bmjopen_2022_064970 crossref_primary_10_1016_S2352_3018_25_00032_3 crossref_primary_10_1093_cid_ciae228 crossref_primary_10_1186_s13011_020_00266_6 crossref_primary_10_1111_hiv_13041 crossref_primary_10_1089_aid_2020_0086 crossref_primary_10_1089_aid_2021_0015 crossref_primary_10_1111_imj_15423 crossref_primary_10_1093_ofid_ofz160 crossref_primary_10_1093_ofid_ofz281 crossref_primary_10_1016_j_jiac_2018_10_006 crossref_primary_10_1186_s12910_018_0321_2 crossref_primary_10_1111_liv_13462 crossref_primary_10_1093_cid_ciz283 crossref_primary_10_1016_S2468_2667_23_00178_0 crossref_primary_10_3928_01477447_20170522_03 crossref_primary_10_3390_cells11040690 crossref_primary_10_1016_j_ijid_2016_10_004 crossref_primary_10_1016_j_jmii_2019_03_008 crossref_primary_10_1097_QAD_0000000000003167 crossref_primary_10_1016_j_pcad_2020_02_003 crossref_primary_10_1038_s41598_020_65841_0 crossref_primary_10_1111_hiv_13279 crossref_primary_10_1371_journal_pone_0129550 crossref_primary_10_4103_JMAU_JMAU_16_20 crossref_primary_10_1097_QAD_0000000000003170 crossref_primary_10_1093_ofid_ofy086 crossref_primary_10_3851_IMP2910 crossref_primary_10_2217_fvl_2019_0066 crossref_primary_10_1097_CM9_0000000000002502 crossref_primary_10_1371_journal_pone_0142515 crossref_primary_10_1093_infdis_jiy331 crossref_primary_10_1111_ajt_13308 crossref_primary_10_3390_life13101975 crossref_primary_10_1007_s11883_015_0545_2 crossref_primary_10_1093_jac_dkae465 crossref_primary_10_1007_s10461_016_1634_0 crossref_primary_10_1097_QCO_0000000000000840 crossref_primary_10_1093_cid_ciz1181 crossref_primary_10_3390_diagnostics12112590 crossref_primary_10_1080_07347332_2020_1867691 crossref_primary_10_6061_clinics_2019_e941 crossref_primary_10_1002_jhm_2409 crossref_primary_10_1016_j_idc_2017_07_007 crossref_primary_10_14309_ajg_0000000000002700 crossref_primary_10_1177_1049909120971826 crossref_primary_10_3389_fpsyt_2016_00102 crossref_primary_10_1016_j_jiph_2024_102567 crossref_primary_10_1093_ofid_ofaa645 crossref_primary_10_1007_s10461_021_03327_4 crossref_primary_10_1002_pds_5379 crossref_primary_10_3390_cells10020410 crossref_primary_10_1186_s12963_017_0135_3 crossref_primary_10_1016_j_ejim_2017_10_012 crossref_primary_10_4291_wjgp_v12_i4_59 crossref_primary_10_1002_hep_31177 crossref_primary_10_5306_wjco_v9_i5_71 crossref_primary_10_1016_j_ebiom_2024_105054 crossref_primary_10_1513_AnnalsATS_201807_460OC crossref_primary_10_1093_cid_ciw804 crossref_primary_10_3390_diagnostics12123147 crossref_primary_10_1016_j_micpath_2019_103804 crossref_primary_10_1016_j_jtho_2016_06_026 crossref_primary_10_1093_ofid_ofy144 crossref_primary_10_1056_NEJMoa1503153 crossref_primary_10_1097_QAI_0000000000001075 crossref_primary_10_3389_fpubh_2019_00266 crossref_primary_10_1097_QAI_0000000000002286 crossref_primary_10_1371_journal_ppat_1008744 crossref_primary_10_1080_09540121_2024_2383871 crossref_primary_10_1016_S2352_3018_16_30052_2 crossref_primary_10_1097_QAD_0000000000000921 crossref_primary_10_2196_24731 crossref_primary_10_1097_QAD_0000000000000922 crossref_primary_10_1111_liv_13021 crossref_primary_10_1093_infdis_jiae212 crossref_primary_10_1089_jwh_2023_0230 crossref_primary_10_3389_fimmu_2021_637910 crossref_primary_10_1186_s12916_020_01762_z crossref_primary_10_1007_s10096_016_2692_y crossref_primary_10_1093_ofid_ofy028 crossref_primary_10_1097_COH_0000000000000118 crossref_primary_10_1007_s11901_019_00501_0 crossref_primary_10_3390_microorganisms11102426 crossref_primary_10_1016_j_pcad_2020_01_002 crossref_primary_10_1371_journal_ppat_1007883 crossref_primary_10_3389_fimmu_2021_632119 crossref_primary_10_1016_j_bulcan_2021_01_026 crossref_primary_10_1186_s12879_017_2708_y crossref_primary_10_1007_s11904_015_0284_6 crossref_primary_10_1093_ofid_ofaa226 crossref_primary_10_1097_MD_0000000000021270 crossref_primary_10_1111_sdi_12765 crossref_primary_10_1007_s11606_019_05416_6 crossref_primary_10_1089_aid_2022_0063 crossref_primary_10_1093_jncics_pkab058 crossref_primary_10_1111_jvh_13863 crossref_primary_10_1186_s12977_018_0458_6 crossref_primary_10_1002_ehf2_12087 crossref_primary_10_1002_hep4_1030 crossref_primary_10_1080_03007995_2023_2224165 crossref_primary_10_3390_ijerph20065090 crossref_primary_10_1089_aid_2022_0069 crossref_primary_10_3945_jn_116_243832 crossref_primary_10_1186_s12879_018_3518_6 crossref_primary_10_1002_14651858_CD011120_pub3 crossref_primary_10_1016_S2352_3018_20_30036_9 crossref_primary_10_1186_s12981_018_0211_1 crossref_primary_10_1093_ofid_ofab309 crossref_primary_10_1016_S0140_6736_18_31311_4 crossref_primary_10_1093_ofid_ofaa215 crossref_primary_10_1097_PPO_0000000000000448 crossref_primary_10_1097_QAD_0000000000000934 crossref_primary_10_1111_apm_13020 crossref_primary_10_1097_QAD_0000000000000943 crossref_primary_10_4102_sajhivmed_v26i1_1679 crossref_primary_10_1007_s11908_015_0471_z crossref_primary_10_1152_japplphysiol_00989_2014 crossref_primary_10_1186_s13063_021_05777_6 crossref_primary_10_1249_FIT_0000000000000308 crossref_primary_10_1097_QAI_0000000000002269 crossref_primary_10_1177_03000605241245011 crossref_primary_10_1089_aid_2019_0064 crossref_primary_10_1093_cid_ciaa1016 crossref_primary_10_1093_infdis_jiw082 crossref_primary_10_1097_COH_0000000000000342 crossref_primary_10_1093_cid_ciy1082 crossref_primary_10_4102_phcfm_v7i1_883 crossref_primary_10_1016_j_dsx_2022_102679 crossref_primary_10_3389_fimmu_2020_01223 crossref_primary_10_1177_2042098620976953 crossref_primary_10_1186_s12879_024_09112_7 crossref_primary_10_1111_tid_13171 crossref_primary_10_1016_j_bjid_2017_06_007 crossref_primary_10_1111_jvh_12554 crossref_primary_10_1097_QAI_0000000000001287 crossref_primary_10_1371_journal_pone_0161594 crossref_primary_10_1007_s10461_017_1859_6 crossref_primary_10_1007_s15006_020_0641_2 crossref_primary_10_3390_v14010135 crossref_primary_10_1002_cncr_34166 crossref_primary_10_1371_journal_pone_0140877 crossref_primary_10_1093_cid_ciaa396 crossref_primary_10_1093_cid_ciad422 crossref_primary_10_1111_imj_14744 crossref_primary_10_1590_s2237_96222022000200021 crossref_primary_10_1371_journal_pone_0232977 crossref_primary_10_1002_cncr_31838 crossref_primary_10_1371_journal_pone_0226182 crossref_primary_10_1097_QAD_0000000000000722 crossref_primary_10_3390_jcm11071804 crossref_primary_10_1007_s11908_015_0514_5 crossref_primary_10_1007_s11904_020_00531_0 crossref_primary_10_1111_hiv_12916 crossref_primary_10_7759_cureus_24540 crossref_primary_10_1016_j_bcp_2017_07_001 crossref_primary_10_1186_s12879_017_2254_7 crossref_primary_10_1371_journal_pone_0208635 crossref_primary_10_1371_journal_pone_0184583 crossref_primary_10_1038_srep28324 crossref_primary_10_1093_aje_kwz236 crossref_primary_10_1093_cid_ciaa026 crossref_primary_10_1093_ofid_ofw173 crossref_primary_10_1093_ofid_ofx264 crossref_primary_10_1093_cid_ciab594 crossref_primary_10_3390_cancers14246129 crossref_primary_10_3390_tropicalmed6040213 crossref_primary_10_1093_tbm_ibab125 crossref_primary_10_1161_CIRCULATIONAHA_118_033913 crossref_primary_10_1097_QAD_0000000000001701 crossref_primary_10_1097_QAI_0000000000001942 crossref_primary_10_1080_17474124_2019_1614441 crossref_primary_10_1002_jia2_26072 crossref_primary_10_1080_17474124_2019_1599284 crossref_primary_10_1093_ofid_ofy121 crossref_primary_10_3390_jcm14175941 crossref_primary_10_3389_fimmu_2025_1469473 crossref_primary_10_1164_rccm_201711_2271ED crossref_primary_10_1371_journal_pone_0150781 crossref_primary_10_1093_cid_ciw621 crossref_primary_10_1016_j_eclinm_2025_103521 crossref_primary_10_1177_2050312119842268 crossref_primary_10_1186_s12879_016_1735_4 crossref_primary_10_1371_journal_ppat_1006624 crossref_primary_10_1111_hiv_12937 crossref_primary_10_3389_fpubh_2024_1322460 crossref_primary_10_34067_KID_0002112020 crossref_primary_10_1016_j_rec_2016_10_005 crossref_primary_10_1186_s12916_019_1433_3 crossref_primary_10_1111_acer_14130 crossref_primary_10_7759_cureus_15932 crossref_primary_10_1097_HC9_0000000000000468 crossref_primary_10_1007_s40506_016_0097_1 crossref_primary_10_1186_s12879_018_3278_3 crossref_primary_10_1016_j_csbj_2023_06_010 crossref_primary_10_1038_s41541_019_0117_5 crossref_primary_10_1007_s40121_018_0210_5 crossref_primary_10_1111_ajt_16886 crossref_primary_10_1371_journal_pone_0152970 crossref_primary_10_3389_fpubh_2022_833551 crossref_primary_10_1093_infdis_jiae007 crossref_primary_10_1089_aid_2017_0008 crossref_primary_10_7759_cureus_19046 crossref_primary_10_1186_s12876_020_01372_2 crossref_primary_10_1007_s15010_022_01887_8 crossref_primary_10_1093_ofid_ofy138 crossref_primary_10_1080_23744235_2019_1707279 crossref_primary_10_1371_journal_pone_0160460 crossref_primary_10_1007_s10903_019_00890_w crossref_primary_10_1016_j_medcli_2019_12_001 crossref_primary_10_1016_j_jana_2014_12_006 crossref_primary_10_1007_s11904_018_0387_y crossref_primary_10_1080_14740338_2021_1935863 crossref_primary_10_1146_annurev_med_052915_015720 crossref_primary_10_1016_j_jhep_2016_09_004 crossref_primary_10_1371_journal_pone_0195031 crossref_primary_10_1136_bmjopen_2021_055706 crossref_primary_10_1016_S2352_3018_18_30110_3 crossref_primary_10_1093_ofid_ofae326 crossref_primary_10_1097_QAD_0000000000001977 crossref_primary_10_1016_j_medcle_2019_12_006 crossref_primary_10_1136_openhrt_2016_000511 crossref_primary_10_1136_thoraxjnl_2016_208657 crossref_primary_10_1002_jia2_25031 crossref_primary_10_1016_j_lungcan_2015_11_021 crossref_primary_10_1002_jia2_25274 crossref_primary_10_1016_j_ahj_2019_07_005 crossref_primary_10_1016_j_eimce_2023_03_002 crossref_primary_10_1093_cid_ciw537 crossref_primary_10_1177_0003319718801093 crossref_primary_10_1080_10428194_2021_2023741 crossref_primary_10_1007_s00535_017_1427_x crossref_primary_10_2147_HMER_S365443 crossref_primary_10_1002_path_4449 crossref_primary_10_1093_cid_ciw531 crossref_primary_10_1186_s12955_021_01777_x crossref_primary_10_1097_QAD_0000000000001504 crossref_primary_10_1093_ofid_ofae308 crossref_primary_10_1093_infdis_jiv005 crossref_primary_10_1097_ID9_0000000000000044 crossref_primary_10_1111_hiv_12822 crossref_primary_10_1177_0956462416651528 crossref_primary_10_1080_14787210_2020_1757430 crossref_primary_10_1097_MD_0000000000002127 crossref_primary_10_1093_infdis_jiaf270 crossref_primary_10_1158_1055_9965_EPI_24_1421 crossref_primary_10_1200_JGO_18_00187 crossref_primary_10_1371_journal_pone_0244742 crossref_primary_10_2196_45818 crossref_primary_10_1007_s40121_018_0201_6 crossref_primary_10_1097_COH_0000000000000292 crossref_primary_10_1097_IPC_0000000000001165 crossref_primary_10_1007_s11904_015_0276_6 crossref_primary_10_1111_hepr_12866 crossref_primary_10_4049_jimmunol_2000430 crossref_primary_10_1002_hep_28766 crossref_primary_10_1093_cid_cix998 crossref_primary_10_1016_j_omtn_2022_06_002 crossref_primary_10_1080_09540121_2025_2534111 crossref_primary_10_1016_S1473_3099_14_70853_9 crossref_primary_10_1097_QAD_0000000000001628 crossref_primary_10_1002_ijc_31081 crossref_primary_10_1097_QAD_0000000000002965 crossref_primary_10_2217_fvl_2020_0184 crossref_primary_10_1016_j_jacc_2017_05_012 crossref_primary_10_1111_hiv_12616 crossref_primary_10_1016_j_ijrobp_2023_01_045 crossref_primary_10_1097_QAD_0000000000001870 crossref_primary_10_1093_ofid_ofy326 crossref_primary_10_1002_jia2_25051 crossref_primary_10_1016_S2352_3018_19_30263_2 crossref_primary_10_1111_hiv_12857 crossref_primary_10_1371_journal_pone_0169246 crossref_primary_10_1097_COH_0000000000000187 crossref_primary_10_5435_JAAOS_D_20_00737 crossref_primary_10_1016_j_canep_2017_11_004 crossref_primary_10_3390_cells10102739 crossref_primary_10_1093_ofid_ofw032 crossref_primary_10_1128_spectrum_00809_25 crossref_primary_10_1111_jre_12460 crossref_primary_10_1093_ofid_ofv066 crossref_primary_10_1097_COH_0000000000000183 crossref_primary_10_1097_MD_0000000000026588 crossref_primary_10_2217_fvl_2019_0131 crossref_primary_10_1007_s11845_019_02063_y crossref_primary_10_2174_1874613601812010162 crossref_primary_10_1093_ofid_ofab389 crossref_primary_10_1111_ctr_14048 crossref_primary_10_1097_QAD_0000000000001525 crossref_primary_10_1097_QAD_0000000000003822 crossref_primary_10_1097_QAD_0000000000000674 crossref_primary_10_1097_QAD_0000000000000795 crossref_primary_10_3390_jcm8081125 crossref_primary_10_1093_cid_ciac978 crossref_primary_10_1016_j_cct_2017_06_012 crossref_primary_10_1093_cid_ciy508 crossref_primary_10_1177_0956462416632428 crossref_primary_10_1016_S2352_3018_24_00063_8 crossref_primary_10_1111_hiv_12761 crossref_primary_10_3389_fmicb_2020_01197 crossref_primary_10_1016_j_cld_2018_12_011 crossref_primary_10_1517_14712598_2015_967208 crossref_primary_10_1097_HCO_0000000000000513 crossref_primary_10_1093_ofid_ofae246 crossref_primary_10_1097_QAD_0000000000002748 crossref_primary_10_1007_s11904_016_0327_7 crossref_primary_10_1007_s12350_019_01676_1 crossref_primary_10_1016_j_clbc_2025_03_017 crossref_primary_10_1016_j_coviro_2016_09_001 crossref_primary_10_1111_hiv_12639 crossref_primary_10_1097_QAD_0000000000003952 crossref_primary_10_1186_s12879_017_2199_x crossref_primary_10_1097_COH_0000000000000952 crossref_primary_10_1016_j_rceng_2017_10_001 crossref_primary_10_1038_s41598_018_37148_8 crossref_primary_10_1097_JCMA_0000000000000528 crossref_primary_10_2147_HIV_S519939 crossref_primary_10_2989_16085906_2019_1686033 crossref_primary_10_1007_s00508_016_1162_y crossref_primary_10_1016_S2352_3018_19_30338_8 crossref_primary_10_1093_cid_ciw219 crossref_primary_10_1007_s11904_023_00657_x crossref_primary_10_1371_journal_pone_0179493 crossref_primary_10_1002_hep_29642 crossref_primary_10_1007_s11904_019_00440_x crossref_primary_10_1093_cid_cix547 crossref_primary_10_1080_09540121_2018_1510110 crossref_primary_10_4254_wjh_v16_i3_452 crossref_primary_10_1097_QAI_0000000000000696 crossref_primary_10_1038_srep39738 crossref_primary_10_1111_hiv_12502 crossref_primary_10_3389_fgene_2022_1020871 crossref_primary_10_1093_cid_ciaa413 crossref_primary_10_1371_journal_pone_0206745 crossref_primary_10_1016_j_lanwpc_2023_100749 crossref_primary_10_1186_s12916_018_1046_2 crossref_primary_10_1186_s12882_022_02693_y crossref_primary_10_1016_j_tranon_2021_101153 crossref_primary_10_1186_s12889_016_3804_4 crossref_primary_10_1186_s12890_021_01792_0 crossref_primary_10_1007_s12308_017_0294_y crossref_primary_10_1093_cid_ciw223 crossref_primary_10_1093_cid_cix311 crossref_primary_10_1093_cid_civ016 crossref_primary_10_1016_j_eimce_2021_07_003 crossref_primary_10_1016_j_gtc_2017_01_007 crossref_primary_10_1097_QAD_0000000000002518 crossref_primary_10_1097_ID9_0000000000000152 crossref_primary_10_1097_QAD_0000000000002889 crossref_primary_10_1097_QAI_0000000000002627 crossref_primary_10_1111_acer_13204 crossref_primary_10_1002_jmv_24441 crossref_primary_10_1097_QAD_0000000000001432 crossref_primary_10_1016_j_cld_2015_06_008 crossref_primary_10_1016_j_ebiom_2022_104391 crossref_primary_10_1016_j_hivar_2015_02_003 crossref_primary_10_1093_cid_ciac708 crossref_primary_10_1371_journal_ppat_1008081 crossref_primary_10_1080_14787210_2017_1364991 crossref_primary_10_1093_cid_ciaa646 crossref_primary_10_3390_tropicalmed8050243 crossref_primary_10_1136_bmjopen_2021_048744 crossref_primary_10_1590_s1678_9946202466023 crossref_primary_10_3389_fimmu_2021_778746 crossref_primary_10_1017_S0950268823001954 crossref_primary_10_1093_cid_ciz985 crossref_primary_10_1111_echo_15302 crossref_primary_10_1093_ofid_ofac279 crossref_primary_10_1097_MD_0000000000004091 crossref_primary_10_3390_healthcare6010017 crossref_primary_10_1161_JAHA_118_011037 crossref_primary_10_1093_ofid_ofac029 crossref_primary_10_32725_jab_2021_002 crossref_primary_10_1093_cid_ciw470 crossref_primary_10_1007_s11904_018_0392_1 crossref_primary_10_1097_QAD_0000000000003862 crossref_primary_10_1097_QAD_0000000000001684 crossref_primary_10_1097_QAD_0000000000002650 crossref_primary_10_1016_S2352_3018_17_30066_8 crossref_primary_10_1111_hiv_12401 crossref_primary_10_1186_s12874_024_02159_9 crossref_primary_10_1007_s10461_025_04844_2 crossref_primary_10_1186_s12876_020_01230_1 crossref_primary_10_1002_jmv_70114 crossref_primary_10_1007_s11908_022_00776_3 crossref_primary_10_1146_annurev_med_060419_122327 crossref_primary_10_1371_journal_pone_0191985 crossref_primary_10_5582_bst_2018_01309 crossref_primary_10_1161_JAHA_120_018074 crossref_primary_10_1186_s12879_021_06082_y crossref_primary_10_1186_s12879_023_08530_3 crossref_primary_10_1371_journal_pone_0250882 crossref_primary_10_1186_s12879_017_2547_x crossref_primary_10_1038_s41598_019_48756_3 crossref_primary_10_9778_cmajo_20180136 crossref_primary_10_1007_s15006_015_3163_6 crossref_primary_10_4254_wjh_v16_i3_366 crossref_primary_10_1016_j_jana_2016_02_006 crossref_primary_10_1002_jcph_762 crossref_primary_10_1016_j_cmi_2025_08_025 crossref_primary_10_1097_QAD_0000000000001334 crossref_primary_10_1097_QAD_0000000000003632 crossref_primary_10_1097_QCO_0000000000000344 crossref_primary_10_1111_hiv_12799 crossref_primary_10_1513_AnnalsATS_201711_904ED crossref_primary_10_1007_s10461_024_04363_6 crossref_primary_10_1080_09540121_2019_1587372 crossref_primary_10_1097_QAD_0000000000001574 crossref_primary_10_1111_hiv_12438 crossref_primary_10_1097_CM9_0000000000003383 crossref_primary_10_1097_QAI_0000000000002721 crossref_primary_10_1097_QAI_0000000000001996 crossref_primary_10_1093_jac_dky316 crossref_primary_10_1016_S2468_1253_16_30120_0 crossref_primary_10_1016_j_jhep_2022_03_007 crossref_primary_10_1186_s12879_018_3336_x crossref_primary_10_1371_journal_pone_0238114 crossref_primary_10_3390_jcm10194460 crossref_primary_10_1093_infdis_jiaa662 crossref_primary_10_1186_s12876_019_0969_1 crossref_primary_10_1097_QAD_0000000000003406 crossref_primary_10_5334_gh_1127 crossref_primary_10_1016_S2352_3018_18_30295_9 crossref_primary_10_1111_ctr_13499 crossref_primary_10_1002_cncr_32563 crossref_primary_10_1111_hiv_12426 crossref_primary_10_1093_ofid_ofv201 crossref_primary_10_1097_QAI_0000000000001984 crossref_primary_10_1016_j_lanepe_2024_100989 crossref_primary_10_1093_ntr_ntz168 crossref_primary_10_1371_journal_pone_0296502 crossref_primary_10_1002_jmv_24357 crossref_primary_10_1093_ofid_ofae266 crossref_primary_10_3389_fendo_2018_00705 crossref_primary_10_1093_cid_ciz539 crossref_primary_10_3390_v14061118 crossref_primary_10_1097_CJI_0000000000000240 crossref_primary_10_9778_cmajo_20180159 crossref_primary_10_1056_NEJMoa1501315 crossref_primary_10_3390_proteomes8030024 crossref_primary_10_1093_cid_ciw380 crossref_primary_10_1097_QAD_0000000000003537 crossref_primary_10_3748_wjg_v30_i14_1958 crossref_primary_10_1002_jia2_25219 crossref_primary_10_1016_j_cmi_2020_09_048 crossref_primary_10_1007_s10461_015_1211_y crossref_primary_10_1016_j_cgh_2020_10_018 crossref_primary_10_1097_QAD_0000000000001112 crossref_primary_10_1007_s10620_020_06355_7 crossref_primary_10_1093_cid_ciaa969 crossref_primary_10_1007_s11904_016_0301_4 crossref_primary_10_1080_23744235_2016_1212168 crossref_primary_10_1136_bmjopen_2021_058231 crossref_primary_10_1007_s10461_018_2269_0 crossref_primary_10_1007_s13365_018_0630_8 crossref_primary_10_1007_s10620_018_5215_0 crossref_primary_10_1111_hiv_12690 crossref_primary_10_1093_ofid_ofae132 crossref_primary_10_1097_QAI_0000000000002812 crossref_primary_10_3390_cells10071687 crossref_primary_10_1182_blood_2018_01_791400 crossref_primary_10_1097_QAI_0000000000000751 crossref_primary_10_1097_QCO_0000000000000117 crossref_primary_10_3390_molecules24091718 crossref_primary_10_1097_QAD_0000000000003302 crossref_primary_10_1007_s11325_019_01993_2 crossref_primary_10_1136_bmjopen_2023_080606 crossref_primary_10_1080_09540121_2022_2129562 crossref_primary_10_1097_QAD_0000000000003540 crossref_primary_10_1097_QAI_0000000000001840 crossref_primary_10_1097_QAI_0000000000001842 crossref_primary_10_1111_hiv_12687
Cites_doi	10.1093/ije/dyr164 10.1186/1471-2334-13-471 10.1097/00002030-200305230-00010 10.3851/IMP2450 10.1007/s15010-012-0293-y 10.1001/archinte.166.15.1632 10.1093/cid/cis919 10.1016/j.amepre.2012.07.032 10.1097/QAD.0b013e32833a0918 10.1097/QAD.0b013e328352ada4 10.3322/caac.21166 10.1086/652283 10.1111/j.1468-1293.2012.01051.x 10.1097/EDE.0b013e31821b5332 10.1097/QAD.0b013e328353f38e 10.1097/QAD.0b013e32834dcec9 10.1097/00126334-200308010-00014 10.1111/j.1365-2893.2009.01261.x 10.1016/S0140-6736(08)60423-7 10.1086/649897 10.1016/j.idc.2012.08.004 10.1097/QAI.0b013e31825a3668 10.2105/AJPH.2009.188664 10.1371/journal.pmed.0050203 10.1136/bmj.b2393 10.1097/QAD.0b013e3283574e94 10.1097/QAD.0b013e3283174636
ContentType	Journal Article
Contributor	Franquet, X Kesselring, A M van der Meer, J T M Lundgren, J D Weber, R Mansfeld, M Rickenbach, M Helweg-Larsen, J Vrouenraets, S M E Kamara, D A van der Poll, T Krum, E Ross, M Moecklinghoff, C Schmidt Iversen, J Fontas, E Donald, A Reilly, G Friis-Møller, N Bower, M de Vries-Sluijs, T E M S Prins, J M Sjøl, A van der Valk, M Pradier, C Oude Lashof, A Fätkenheuer, G Sabin, C Geffard, S Scherpbier, H J Kamara, D Nouwen, J L Law, M Raben, D Schurink, C A M Wright, S Ryom, L Boer, K d'Arminio Monforte, A Mocroft, A Fanti, I van der Ende, M E Torres, F Smith, C Kuijpers, T W Nellen, F J B Lange, J M A Bruyand, M Gelinck, L B S Tverland, J Kirk, O Grulich, A Pronk, M J H Nielsen, J Gras, L Shortman, N Morlat, P Kjær, J Geerlings, S E Hillebregt, M Schreij, G Dabis, F Godfried, M H Kowalska, J Wit, F W M N Pajkrt, D Reiss, P Fux, C A McManus, H van der Feltz, M Moranne, O Bravenboer, B Lowe, S Powderly, B Salbøl Brandt, R Sabin, C A Meidahl, P Phillips, A Sundström, A Delforge, M van Vugt, M Zaheri, S
Contributor_xml	– sequence: 1 givenname: B surname: Powderly fullname: Powderly, B – sequence: 2 givenname: N surname: Shortman fullname: Shortman, N – sequence: 3 givenname: C surname: Moecklinghoff fullname: Moecklinghoff, C – sequence: 4 givenname: G surname: Reilly fullname: Reilly, G – sequence: 5 givenname: X surname: Franquet fullname: Franquet, X – sequence: 6 givenname: L surname: Ryom fullname: Ryom, L – sequence: 7 givenname: C A surname: Sabin fullname: Sabin, C A – sequence: 8 givenname: D surname: Kamara fullname: Kamara, D – sequence: 9 givenname: C surname: Smith fullname: Smith, C – sequence: 10 givenname: A surname: Phillips fullname: Phillips, A – sequence: 11 givenname: A surname: Mocroft fullname: Mocroft, A – sequence: 12 givenname: J surname: Tverland fullname: Tverland, J – sequence: 13 givenname: M surname: Mansfeld fullname: Mansfeld, M – sequence: 14 givenname: J surname: Nielsen fullname: Nielsen, J – sequence: 15 givenname: D surname: Raben fullname: Raben, D – sequence: 16 givenname: J D surname: Lundgren fullname: Lundgren, J D – sequence: 17 givenname: R surname: Salbøl Brandt fullname: Salbøl Brandt, R – sequence: 18 givenname: M surname: Rickenbach fullname: Rickenbach, M – sequence: 19 givenname: I surname: Fanti fullname: Fanti, I – sequence: 20 givenname: E surname: Krum fullname: Krum, E – sequence: 21 givenname: M surname: Hillebregt fullname: Hillebregt, M – sequence: 22 givenname: S surname: Geffard fullname: Geffard, S – sequence: 23 givenname: A surname: Sundström fullname: Sundström, A – sequence: 24 givenname: M surname: Delforge fullname: Delforge, M – sequence: 25 givenname: E surname: Fontas fullname: Fontas, E – sequence: 26 givenname: F surname: Torres fullname: Torres, F – sequence: 27 givenname: H surname: McManus fullname: McManus, H – sequence: 28 givenname: S surname: Wright fullname: Wright, S – sequence: 29 givenname: J surname: Kjær fullname: Kjær, J – sequence: 30 givenname: A surname: Sjøl fullname: Sjøl, A – sequence: 31 givenname: P surname: Meidahl fullname: Meidahl, P – sequence: 32 givenname: J surname: Helweg-Larsen fullname: Helweg-Larsen, J – sequence: 33 givenname: J surname: Schmidt Iversen fullname: Schmidt Iversen, J – sequence: 34 givenname: O surname: Kirk fullname: Kirk, O – sequence: 35 givenname: P surname: Reiss fullname: Reiss, P – sequence: 36 givenname: M surname: Ross fullname: Ross, M – sequence: 37 givenname: C A surname: Fux fullname: Fux, C A – sequence: 38 givenname: P surname: Morlat fullname: Morlat, P – sequence: 39 givenname: O surname: Moranne fullname: Moranne, O – sequence: 40 givenname: A M surname: Kesselring fullname: Kesselring, A M – sequence: 41 givenname: D A surname: Kamara fullname: Kamara, D A – sequence: 42 givenname: R surname: Weber fullname: Weber, R – sequence: 43 givenname: C surname: Pradier fullname: Pradier, C – sequence: 44 givenname: N surname: Friis-Møller fullname: Friis-Møller, N – sequence: 45 givenname: J surname: Kowalska fullname: Kowalska, J – sequence: 46 givenname: C surname: Sabin fullname: Sabin, C – sequence: 47 givenname: M surname: Law fullname: Law, M – sequence: 48 givenname: A surname: d'Arminio Monforte fullname: d'Arminio Monforte, A – sequence: 49 givenname: F surname: Dabis fullname: Dabis, F – sequence: 50 givenname: M surname: Bruyand fullname: Bruyand, M – sequence: 51 givenname: M surname: Bower fullname: Bower, M – sequence: 52 givenname: G surname: Fätkenheuer fullname: Fätkenheuer, G – sequence: 53 givenname: A surname: Donald fullname: Donald, A – sequence: 54 givenname: A surname: Grulich fullname: Grulich, A – sequence: 55 givenname: S surname: Zaheri fullname: Zaheri, S – sequence: 56 givenname: L surname: Gras fullname: Gras, L – sequence: 57 givenname: J M surname: Prins fullname: Prins, J M – sequence: 58 givenname: T W surname: Kuijpers fullname: Kuijpers, T W – sequence: 59 givenname: H J surname: Scherpbier fullname: Scherpbier, H J – sequence: 60 givenname: K surname: Boer fullname: Boer, K – sequence: 61 givenname: J T M surname: van der Meer fullname: van der Meer, J T M – sequence: 62 givenname: F W M N surname: Wit fullname: Wit, F W M N – sequence: 63 givenname: M H surname: Godfried fullname: Godfried, M H – sequence: 64 givenname: T surname: van der Poll fullname: van der Poll, T – sequence: 65 givenname: F J B surname: Nellen fullname: Nellen, F J B – sequence: 66 givenname: J M A surname: Lange fullname: Lange, J M A – sequence: 67 givenname: S E surname: Geerlings fullname: Geerlings, S E – sequence: 68 givenname: M surname: van Vugt fullname: van Vugt, M – sequence: 69 givenname: S M E surname: Vrouenraets fullname: Vrouenraets, S M E – sequence: 70 givenname: D surname: Pajkrt fullname: Pajkrt, D – sequence: 71 givenname: M surname: van der Valk fullname: van der Valk, M – sequence: 72 givenname: G surname: Schreij fullname: Schreij, G – sequence: 73 givenname: S surname: Lowe fullname: Lowe, S – sequence: 74 givenname: A surname: Oude Lashof fullname: Oude Lashof, A – sequence: 75 givenname: M J H surname: Pronk fullname: Pronk, M J H – sequence: 76 givenname: B surname: Bravenboer fullname: Bravenboer, B – sequence: 77 givenname: M E surname: van der Ende fullname: van der Ende, M E – sequence: 78 givenname: T E M S surname: de Vries-Sluijs fullname: de Vries-Sluijs, T E M S – sequence: 79 givenname: C A M surname: Schurink fullname: Schurink, C A M – sequence: 80 givenname: M surname: van der Feltz fullname: van der Feltz, M – sequence: 81 givenname: J L surname: Nouwen fullname: Nouwen, J L – sequence: 82 givenname: L B S surname: Gelinck fullname: Gelinck, L B S
Copyright	2014 Elsevier Ltd Elsevier Ltd 2015 INIST-CNRS Copyright © 2014 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Jul 19, 2014
Copyright_xml	– notice: 2014 Elsevier Ltd – notice: Elsevier Ltd – notice: 2015 INIST-CNRS – notice: Copyright © 2014 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Jul 19, 2014
CorporateAuthor	for the D:A:D Study Group D:A:D Study Group
CorporateAuthor_xml	– name: for the D:A:D Study Group – name: D:A:D Study Group
DBID	AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7RV 7TK 7U7 7U9 7X7 7XB 88A 88C 88E 88G 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AN0 ASE AZQEC BBNVY BEC BENPR BHPHI C1K CCPQU DWQXO FPQ FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K6X K9- K9. KB0 KB~ LK8 M0R M0S M0T M1P M2M M2O M2P M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U S0X 7X8
DOI	10.1016/S0140-6736(14)60604-8
DatabaseName	CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Public Health Database Lancet Titles ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland British Nursing Database British Nursing Index ProQuest Central Essentials ProQuest SciTech Premium Collection Natural Science Collection Biological Science Collection eLibrary ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea British Nursing Index (BNI) (1985 to Present) Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Collection (ProQuest) British Nursing Index Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Newsstand Professional ProQuest Biological Science Collection Consumer Health Database Health & Medical Collection (Alumni Edition) Healthcare Administration Database Medical Database Psychology Database (ProQuest) Research Library (ProQuest) Science Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest One Academic ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic SIRS Editorial MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest Central Essentials Lancet Titles elibrary ProQuest AP Science SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Newsstand Professional Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals British Nursing Index with Full Text ProQuest Health Management British Nursing Index ProQuest Nursing & Allied Health Source ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection ProQuest Medical Library ProQuest Psychology Journals ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE ProQuest One Psychology
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Public Health
EISSN	1474-547X
EndPage	248
ExternalDocumentID	3376796601 25042234 28691043 10_1016_S0140_6736_14_60604_8 S0140673614606048 1_s2_0_S0140673614606048
Genre	Research Support, Non-U.S. Gov't Journal Article
GeographicLocations	Australia United States Europe
GeographicLocations_xml	– name: Europe – name: Australia – name: United States
GrantInformation	Oversight Committee for the Evaluation of Metabolic Complications of HAART, with representatives from academia, patient community, US Food and Drug Administration, European Medicines Agency and consortium of AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, ViiV Healthcare, Merck, Pfizer, F Hoffmann-La Roche, and Janssen Pharmaceuticals.
GrantInformation_xml	– fundername: Medical Research Council grantid: G0701639
GroupedDBID	--- --K --M .1- .55 .CO .FO 0R~ 123 1B1 1P~ 1RT 1~5 29L 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8G5 9JM AABNK AAEDT AAEDW AAFWJ AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AATTM AAXKI AAXUO AAYWO ABBQC ABCQX ABFNM ABIVO ABJNI ABLJU ABMAC ABMZM ABOCM ABUFD ABUWG ACGFS ACGOD ACIEU ACIUM ACLOT ACPRK ACRLP ACVFH ADBBV ADCNI AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGAPS AGHFR AHHHB AHMBA AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AN0 ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BCU BEC BENPR BHPHI BKEYQ BKNYI BKOJK BKOMP BNPGV BNQBC BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EAU EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EWM EX3 F5P FD8 FDB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K-O K9- KOM L7B LK8 LZ2 M0R M0T M1P M2M M2O M2P M7P MJL MO0 N9A NAPCQ O-L O9- OD. OO~ OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PRG PROAC PSQYO PSYQQ R2- ROL RPZ S0X SAD SDG SEL SES SJFOW SJN SPCBC SSH SSZ T5K TLN TWZ UAP UBE UKHRP UQL UV1 WOW X7M XAX XDU YYM Z5R ZMT ~HD .GJ 04C 3EH 3O- 3V. 41~ 88A 8WZ A6W AACTN AAEJM AAKAS AAQXK AAYOK ABDBF ABTAH ABWVN ACRPL ACRZS ACUHS ADMUD ADNMO ADZCM AFCTW AFFNX AFKWA AHQJS AJJEV AJOXV AKVCP ALIPV AMFUW ARTTT ASPBG AVWKF AZFZN D0S EAP EAS EAZ EBC EBD EBU EGS EHN EIHBH EMB EMK EMOBN ENC EPL EPS EPT ESX EVS FEDTE FGOYB HVGLF HZ~ J5H M0L M41 MVM OVD PKN Q~Q RIG SDF SV3 TEORI TH9 UHU WOQ WUQ XPP YYQ ZGI ZXP ZY4 ~G0 ABLVK ABYKQ AHPSJ AJBFU XFK ZA5 9DU AAYXX ADXHL AFFHD AGQPQ AIGII CITATION IQODW AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7QL 7QP 7TK 7U7 7U9 7XB 8FK ASE C1K FPQ H94 K6X K9. KB~ M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO
ID	FETCH-LOGICAL-c579t-8a6276ccb7471b8983d0730aeb9683729ba7dada32fe7d4c9f50a7d44f63b0c23
IEDL.DBID	M7P
ISICitedReferencesCount	761
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000339384100025&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0140-6736 1474-547X
IngestDate	Thu Oct 02 06:19:30 EDT 2025 Sun Oct 26 18:19:10 EDT 2025 Mon Jul 21 06:05:56 EDT 2025 Wed Apr 02 07:16:11 EDT 2025 Sat Nov 29 05:12:21 EST 2025 Tue Nov 18 22:39:20 EST 2025 Fri Feb 23 02:30:16 EST 2024 Sun Feb 23 10:19:31 EST 2025 Tue Oct 14 19:29:41 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	9939
Keywords	Immunopathology Mortality Retroviridae Trend AIDS Immune deficiency Lentivirus Infection Virus Medicine Etiology Viral disease Cooperation Cause Death Human immunodeficiency virus Causality 1999
Language	English
License	CC BY 4.0 Copyright © 2014 Elsevier Ltd. All rights reserved.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c579t-8a6276ccb7471b8983d0730aeb9683729ba7dada32fe7d4c9f50a7d44f63b0c23
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
OpenAccessLink	http://www.thelancet.com/article/S0140673614606048/pdf
PMID	25042234
PQID	1545851693
PQPubID	40246
PageCount	8
ParticipantIDs	proquest_miscellaneous_1547541527 proquest_journals_1545851693 pubmed_primary_25042234 pascalfrancis_primary_28691043 crossref_citationtrail_10_1016_S0140_6736_14_60604_8 crossref_primary_10_1016_S0140_6736_14_60604_8 elsevier_sciencedirect_doi_10_1016_S0140_6736_14_60604_8 elsevier_clinicalkeyesjournals_1_s2_0_S0140673614606048 elsevier_clinicalkey_doi_10_1016_S0140_6736_14_60604_8
PublicationCentury	2000
PublicationDate	2014-07-19
PublicationDateYYYYMMDD	2014-07-19
PublicationDate_xml	– month: 07 year: 2014 text: 2014-07-19 day: 19
PublicationDecade	2010
PublicationPlace	Kidlington
PublicationPlace_xml	– name: Kidlington – name: England – name: London
PublicationTitle	The Lancet (British edition)
PublicationTitleAlternate	Lancet
PublicationYear	2014
Publisher	Elsevier Ltd Elsevier Elsevier Limited
Publisher_xml	– name: Elsevier Ltd – name: Elsevier – name: Elsevier Limited
References	Lundgren JD for the late presenters working group of COHERE in EuroCoord. Characteristics of individuals with HIV presenting late for care across Europe. XIX International AIDS Conference, Washington DC, USA; July 22–27, 2012. Abstract THAB0303. Kuller, Tracy, Belloso (bib8) 2008; 5 (bib12) 2010; 24 Helleberg, Kronborg, Larsen (bib14) 2012; 40 Bruyand M, Ryom L, Shepherd L, et al. Cancer Risk and Use of Protease Inhibitor- or NNRTI-based cART: The D:A:D Study. 20th Conference on Retroviruses and Opportunistic Infections (CROI), Georgia, Atlanta, USA; March 3–6 2013. Abstract 742b. Sabin C, Ryom L, Law M, et al. Improvements in short-term mortality following myocardial infarction: the data collection on adverse events of anti-HIV drugs study. 20 Phillips, Neaton, Lundgren (bib7) 2008; 22 conference on retroviruses and opportunistic infections (CROI), Georgia, Atlanta, USA; March 3–6, 2013. Abstract 748. Soriano, Labarga, Vispo, Fernández-Montero, Barreiro (bib32) 2012; 26 Conigliaro, Gordon, McGinnis, Rabeneck, Justice (bib22) 2003; 33 Weber, Ruppik, Rickenbach (bib1) 2013; 14 Sabin, Worm, Weber (bib9) 2008; 371 Lifson, Neuhaus, Arribas (bib23) 2010; 100 Horvath, Eastman, Prosser, Goodroad, Worthinton (bib24) 2012; 43 Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Washington, USA; March 3–6, 2012. Abstract 130. Berenguer, Alejos, Hernando (bib17) 2012; 26 Blanco, Barreiro, Ryan (bib34) 2011; 18 Worm, Bower, Reiss (bib20) 2013; 13 Worm, Sabin, Weber (bib30) 2010; 201 Hernando, Sobrino-Vegas, Burriel (bib35) 2012; 26 bib26 Kowalska, Friis-Møller, Kirk (bib10) 2011; 22 Simard, Pfeiffer, Engels (bib15) 2012; 26 Scarborough, Bhatnagar, Wickramasinghe, Smolina, Mitchell, Rayner (bib28) Friis-Moller, Weber, Reiss (bib4) 2003; 17 Kovari, Sabin, Ledergerber (bib31) 2013; 56 Pinzone, Fiorica, Di Rosa (bib25) 2012; 16 Buchasz, Baker, Palella (bib5) 2012; 18 (bib16) 2010; 50 Siegel, Naishadham, Jemal (bib27) 2013; 63 Eayres (bib11) Nakagawa, Lodwick, Smith (bib3) 2012; 26 High, Brennan-Ing, Clifford (bib6) 2012; 60 Weber, Sabin, Friis-Moller (bib33) 2006; 166 (bib2) 2012; 41 Worm SW, Bower M, Reiss P et al. Non-AIDS defining malignancies (NADM) and immunosuppression: The D:A:D study. 19 Sterne, White, Carlin (bib13) 2009; 338 Eayres (10.1016/S0140-6736(14)60604-8_bib11) Horvath (10.1016/S0140-6736(14)60604-8_bib24) 2012; 43 10.1016/S0140-6736(14)60604-8_bib18 Friis-Moller (10.1016/S0140-6736(14)60604-8_bib4) 2003; 17 Kuller (10.1016/S0140-6736(14)60604-8_bib8) 2008; 5 10.1016/S0140-6736(14)60604-8_bib19 Kowalska (10.1016/S0140-6736(14)60604-8_bib10) 2011; 22 Worm (10.1016/S0140-6736(14)60604-8_bib20) 2013; 13 Helleberg (10.1016/S0140-6736(14)60604-8_bib14) 2012; 40 Weber (10.1016/S0140-6736(14)60604-8_bib33) 2006; 166 Sabin (10.1016/S0140-6736(14)60604-8_bib9) 2008; 371 Berenguer (10.1016/S0140-6736(14)60604-8_bib17) 2012; 26 Buchasz (10.1016/S0140-6736(14)60604-8_bib5) 2012; 18 Phillips (10.1016/S0140-6736(14)60604-8_bib7) 2008; 22 Kovari (10.1016/S0140-6736(14)60604-8_bib31) 2013; 56 Hernando (10.1016/S0140-6736(14)60604-8_bib35) 2012; 26 10.1016/S0140-6736(14)60604-8_bib29 (10.1016/S0140-6736(14)60604-8_bib12) 2010; 24 High (10.1016/S0140-6736(14)60604-8_bib6) 2012; 60 Lifson (10.1016/S0140-6736(14)60604-8_bib23) 2010; 100 Siegel (10.1016/S0140-6736(14)60604-8_bib27) 2013; 63 Simard (10.1016/S0140-6736(14)60604-8_bib15) 2012; 26 Pinzone (10.1016/S0140-6736(14)60604-8_bib25) 2012; 16 (10.1016/S0140-6736(14)60604-8_bib16) 2010; 50 Worm (10.1016/S0140-6736(14)60604-8_bib30) 2010; 201 Nakagawa (10.1016/S0140-6736(14)60604-8_bib3) 2012; 26 Blanco (10.1016/S0140-6736(14)60604-8_bib34) 2011; 18 Conigliaro (10.1016/S0140-6736(14)60604-8_bib22) 2003; 33 10.1016/S0140-6736(14)60604-8_bib21 (10.1016/S0140-6736(14)60604-8_bib2) 2012; 41 Sterne (10.1016/S0140-6736(14)60604-8_bib13) 2009; 338 Scarborough (10.1016/S0140-6736(14)60604-8_bib28) Weber (10.1016/S0140-6736(14)60604-8_bib1) 2013; 14 Soriano (10.1016/S0140-6736(14)60604-8_bib32) 2012; 26 25042221 - Lancet. 2014 Jul 19;384(9939):214-6. doi: 10.1016/S0140-6736(14)60848-5.
References_xml	– volume: 371 start-page: 1417 year: 2008 end-page: 1426 ident: bib9 article-title: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multicohort collaboration publication-title: Lancet – volume: 33 start-page: 521 year: 2003 end-page: 525 ident: bib22 article-title: How harmful is hazardous alcohol use and abuse in HIV infection: do health care providers know who is at risk? publication-title: J Acquir Immune Defic Syndr – volume: 63 start-page: 11 year: 2013 end-page: 30 ident: bib27 article-title: Cancer Statistics, 2013 publication-title: CA Cancer J Clin – volume: 17 start-page: 1179 year: 2003 end-page: 1193 ident: bib4 article-title: Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study publication-title: AIDS – volume: 18 start-page: 65 year: 2012 end-page: 75 ident: bib5 article-title: Disparities in prevalence of key chronic disease by gender and race/ethnicity among antiretroviral-treated HIV-infected adults in the US publication-title: Antivir Ther – ident: bib26 article-title: Causes of death statistics – volume: 5 start-page: e203 year: 2008 ident: bib8 article-title: Inflammatory and coagulation biomarkers and mortality in patients with HIV infection publication-title: PLoS Med – volume: 22 start-page: 2409 year: 2008 end-page: 2418 ident: bib7 article-title: The role of HIV in serious diseases other than AIDS publication-title: AIDS – reference: conference on retroviruses and opportunistic infections (CROI), Georgia, Atlanta, USA; March 3–6, 2013. Abstract 748. – volume: 40 start-page: 627 year: 2012 end-page: 634 ident: bib14 article-title: Causes of death among Danish HIV patients compared with population controls in the period 1995–2008 publication-title: Infection – volume: 26 start-page: 1829 year: 2012 end-page: 1834 ident: bib35 article-title: Differences in the causes of death of HIV-positive patients in a cohort study by data sources and coding algorithms publication-title: AIDS – volume: 16 start-page: 1377 year: 2012 end-page: 1388 ident: bib25 article-title: Non-AIDS-defining cancers among HIV-infected people publication-title: Eur Rev Med Pharmacol Sci – volume: 26 start-page: 335 year: 2012 end-page: 343 ident: bib3 article-title: Projected life expectancy of people with HIV according to timing of diagnosis publication-title: AIDS – volume: 14 start-page: 195 year: 2013 end-page: 207 ident: bib1 article-title: Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study publication-title: HIV Med – volume: 41 start-page: 433 year: 2012 end-page: 445 ident: bib2 publication-title: Int J Epidemiol – reference: Lundgren JD for the late presenters working group of COHERE in EuroCoord. Characteristics of individuals with HIV presenting late for care across Europe. XIX International AIDS Conference, Washington DC, USA; July 22–27, 2012. Abstract THAB0303. – volume: 18 start-page: 11 year: 2011 end-page: 16 ident: bib34 article-title: Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance publication-title: J Viral Hepat – volume: 26 start-page: 1311 year: 2012 end-page: 1318 ident: bib15 article-title: Mortality due to cancer among people with AIDS: a novel approach using registry-linkage data and population attributable risk methods publication-title: AIDS – volume: 24 start-page: 1537 year: 2010 end-page: 1548 ident: bib12 article-title: Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study publication-title: AIDS – ident: bib28 article-title: Coronary heart disease statistics 2010 edition. British Heart Foundation statistics database – volume: 26 start-page: 931 year: 2012 end-page: 948 ident: bib32 article-title: Treatment of hepatitis C in patients infected with human immunodeficiency virus in the direct-acting antiviral era publication-title: Infect Dis Clin North Am – volume: 26 start-page: 2241 year: 2012 end-page: 2246 ident: bib17 article-title: Trends in mortality according to hepatitis C virus serostatus in the era of combination antiretroviral therapy publication-title: AIDS – volume: 56 start-page: 870 year: 2013 end-page: 879 ident: bib31 article-title: Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of HBV or HCV co-infection. The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study publication-title: Clin Infect Dis Mar – volume: 60 start-page: S1 year: 2012 end-page: 18 ident: bib6 article-title: HIV and aging: State of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group publication-title: J Acquir Immune Defic Syndr – volume: 50 start-page: 1387 year: 2010 end-page: 1396 ident: bib16 article-title: Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies publication-title: Clin Infect Dis – reference: Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Washington, USA; March 3–6, 2012. Abstract 130. – reference: Worm SW, Bower M, Reiss P et al. Non-AIDS defining malignancies (NADM) and immunosuppression: The D:A:D study. 19 – reference: Bruyand M, Ryom L, Shepherd L, et al. Cancer Risk and Use of Protease Inhibitor- or NNRTI-based cART: The D:A:D Study. 20th Conference on Retroviruses and Opportunistic Infections (CROI), Georgia, Atlanta, USA; March 3–6 2013. Abstract 742b. – volume: 201 start-page: 318 year: 2010 end-page: 330 ident: bib30 article-title: Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study publication-title: J Infect Dis – volume: 166 start-page: 1632 year: 2006 end-page: 1641 ident: bib33 article-title: Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study publication-title: Arch Intern Med – volume: 22 start-page: 516 year: 2011 end-page: 523 ident: bib10 article-title: The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology publication-title: Epidemiology – volume: 100 start-page: 1896 year: 2010 end-page: 1903 ident: bib23 article-title: Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial publication-title: Am J Public Health – ident: bib11 article-title: Technical briefing 3: commonly used public health statistics and their confidence intervals – reference: Sabin C, Ryom L, Law M, et al. Improvements in short-term mortality following myocardial infarction: the data collection on adverse events of anti-HIV drugs study. 20 – volume: 43 start-page: S214 year: 2012 end-page: S221 ident: bib24 article-title: Addressing smoking during medical visits: patients with immunodeficiency virus publication-title: Am J Prev Med – volume: 338 start-page: b2393 year: 2009 ident: bib13 article-title: Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls publication-title: BMJ – volume: 13 start-page: 471 year: 2013 ident: bib20 article-title: Non-AIDs defining cancers in the D:A:D study—time trends and predictors of survival: a cohort study publication-title: BMC Infect Dis – volume: 41 start-page: 433 year: 2012 ident: 10.1016/S0140-6736(14)60604-8_bib2 publication-title: Int J Epidemiol doi: 10.1093/ije/dyr164 – volume: 13 start-page: 471 year: 2013 ident: 10.1016/S0140-6736(14)60604-8_bib20 article-title: Non-AIDs defining cancers in the D:A:D study—time trends and predictors of survival: a cohort study publication-title: BMC Infect Dis doi: 10.1186/1471-2334-13-471 – volume: 17 start-page: 1179 year: 2003 ident: 10.1016/S0140-6736(14)60604-8_bib4 article-title: Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study publication-title: AIDS doi: 10.1097/00002030-200305230-00010 – ident: 10.1016/S0140-6736(14)60604-8_bib19 – volume: 18 start-page: 65 year: 2012 ident: 10.1016/S0140-6736(14)60604-8_bib5 article-title: Disparities in prevalence of key chronic disease by gender and race/ethnicity among antiretroviral-treated HIV-infected adults in the US publication-title: Antivir Ther doi: 10.3851/IMP2450 – volume: 40 start-page: 627 year: 2012 ident: 10.1016/S0140-6736(14)60604-8_bib14 article-title: Causes of death among Danish HIV patients compared with population controls in the period 1995–2008 publication-title: Infection doi: 10.1007/s15010-012-0293-y – volume: 166 start-page: 1632 year: 2006 ident: 10.1016/S0140-6736(14)60604-8_bib33 article-title: Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study publication-title: Arch Intern Med doi: 10.1001/archinte.166.15.1632 – volume: 56 start-page: 870 year: 2013 ident: 10.1016/S0140-6736(14)60604-8_bib31 article-title: Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of HBV or HCV co-infection. The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study publication-title: Clin Infect Dis Mar doi: 10.1093/cid/cis919 – volume: 43 start-page: S214 year: 2012 ident: 10.1016/S0140-6736(14)60604-8_bib24 article-title: Addressing smoking during medical visits: patients with immunodeficiency virus publication-title: Am J Prev Med doi: 10.1016/j.amepre.2012.07.032 – volume: 24 start-page: 1537 year: 2010 ident: 10.1016/S0140-6736(14)60604-8_bib12 article-title: Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study publication-title: AIDS doi: 10.1097/QAD.0b013e32833a0918 – volume: 26 start-page: 1829 year: 2012 ident: 10.1016/S0140-6736(14)60604-8_bib35 article-title: Differences in the causes of death of HIV-positive patients in a cohort study by data sources and coding algorithms publication-title: AIDS doi: 10.1097/QAD.0b013e328352ada4 – volume: 63 start-page: 11 year: 2013 ident: 10.1016/S0140-6736(14)60604-8_bib27 article-title: Cancer Statistics, 2013 publication-title: CA Cancer J Clin doi: 10.3322/caac.21166 – ident: 10.1016/S0140-6736(14)60604-8_bib29 – ident: 10.1016/S0140-6736(14)60604-8_bib21 – volume: 50 start-page: 1387 year: 2010 ident: 10.1016/S0140-6736(14)60604-8_bib16 article-title: Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies publication-title: Clin Infect Dis doi: 10.1086/652283 – volume: 14 start-page: 195 year: 2013 ident: 10.1016/S0140-6736(14)60604-8_bib1 article-title: Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study publication-title: HIV Med doi: 10.1111/j.1468-1293.2012.01051.x – volume: 22 start-page: 516 year: 2011 ident: 10.1016/S0140-6736(14)60604-8_bib10 article-title: The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology publication-title: Epidemiology doi: 10.1097/EDE.0b013e31821b5332 – volume: 26 start-page: 1311 year: 2012 ident: 10.1016/S0140-6736(14)60604-8_bib15 article-title: Mortality due to cancer among people with AIDS: a novel approach using registry-linkage data and population attributable risk methods publication-title: AIDS doi: 10.1097/QAD.0b013e328353f38e – ident: 10.1016/S0140-6736(14)60604-8_bib18 – volume: 16 start-page: 1377 year: 2012 ident: 10.1016/S0140-6736(14)60604-8_bib25 article-title: Non-AIDS-defining cancers among HIV-infected people publication-title: Eur Rev Med Pharmacol Sci – volume: 26 start-page: 335 year: 2012 ident: 10.1016/S0140-6736(14)60604-8_bib3 article-title: Projected life expectancy of people with HIV according to timing of diagnosis publication-title: AIDS doi: 10.1097/QAD.0b013e32834dcec9 – ident: 10.1016/S0140-6736(14)60604-8_bib28 – volume: 33 start-page: 521 year: 2003 ident: 10.1016/S0140-6736(14)60604-8_bib22 article-title: How harmful is hazardous alcohol use and abuse in HIV infection: do health care providers know who is at risk? publication-title: J Acquir Immune Defic Syndr doi: 10.1097/00126334-200308010-00014 – volume: 18 start-page: 11 year: 2011 ident: 10.1016/S0140-6736(14)60604-8_bib34 article-title: Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance publication-title: J Viral Hepat doi: 10.1111/j.1365-2893.2009.01261.x – volume: 371 start-page: 1417 year: 2008 ident: 10.1016/S0140-6736(14)60604-8_bib9 article-title: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multicohort collaboration publication-title: Lancet doi: 10.1016/S0140-6736(08)60423-7 – volume: 201 start-page: 318 year: 2010 ident: 10.1016/S0140-6736(14)60604-8_bib30 article-title: Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study publication-title: J Infect Dis doi: 10.1086/649897 – ident: 10.1016/S0140-6736(14)60604-8_bib11 – volume: 26 start-page: 931 year: 2012 ident: 10.1016/S0140-6736(14)60604-8_bib32 article-title: Treatment of hepatitis C in patients infected with human immunodeficiency virus in the direct-acting antiviral era publication-title: Infect Dis Clin North Am doi: 10.1016/j.idc.2012.08.004 – volume: 60 start-page: S1 year: 2012 ident: 10.1016/S0140-6736(14)60604-8_bib6 article-title: HIV and aging: State of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e31825a3668 – volume: 100 start-page: 1896 year: 2010 ident: 10.1016/S0140-6736(14)60604-8_bib23 article-title: Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial publication-title: Am J Public Health doi: 10.2105/AJPH.2009.188664 – volume: 5 start-page: e203 year: 2008 ident: 10.1016/S0140-6736(14)60604-8_bib8 article-title: Inflammatory and coagulation biomarkers and mortality in patients with HIV infection publication-title: PLoS Med doi: 10.1371/journal.pmed.0050203 – volume: 338 start-page: b2393 year: 2009 ident: 10.1016/S0140-6736(14)60604-8_bib13 article-title: Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls publication-title: BMJ doi: 10.1136/bmj.b2393 – volume: 26 start-page: 2241 year: 2012 ident: 10.1016/S0140-6736(14)60604-8_bib17 article-title: Trends in mortality according to hepatitis C virus serostatus in the era of combination antiretroviral therapy publication-title: AIDS doi: 10.1097/QAD.0b013e3283574e94 – volume: 22 start-page: 2409 year: 2008 ident: 10.1016/S0140-6736(14)60604-8_bib7 article-title: The role of HIV in serious diseases other than AIDS publication-title: AIDS doi: 10.1097/QAD.0b013e3283174636 – reference: 25042221 - Lancet. 2014 Jul 19;384(9939):214-6. doi: 10.1016/S0140-6736(14)60848-5.
SSID	ssj0004605
Score	2.6417325
Snippet	With the advent of effective antiretroviral treatment, the life expectancy for people with HIV is now approaching that seen in the general population.... Summary Background With the advent of effective antiretroviral treatment, the life expectancy for people with HIV is now approaching that seen in the general...
SourceID	proquest pubmed pascalfrancis crossref elsevier
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	241
SubjectTerms	Acquired immune deficiency syndrome Acquired Immunodeficiency Syndrome - mortality Adult AIDS Antiretroviral agents Antiretroviral drugs Australia - epidemiology Biological and medical sciences Cardiovascular diseases Cause of Death - trends Data collection Europe - epidemiology Female General aspects HIV HIV Infections - mortality Human immunodeficiency virus Human viral diseases Humans Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Infectious diseases Internal Medicine Life expectancy Liver Male Medical sciences Middle Aged Mortality Poisson Distribution Public health Risk Factors United States - epidemiology Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids
Title	Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S0140673614606048 https://www.clinicalkey.es/playcontent/1-s2.0-S0140673614606048 https://dx.doi.org/10.1016/S0140-6736(14)60604-8 https://www.ncbi.nlm.nih.gov/pubmed/25042234 https://www.proquest.com/docview/1545851693 https://www.proquest.com/docview/1547541527
Volume	384
WOSCitedRecordID	wos000339384100025&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M7P dateStart: 19920104 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M0R dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 7X7 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M0T dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 7RV dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: BENPR dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2M dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 8C1 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2O dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1474-547X dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2P dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Za9tAEB6apJRC6JEeUZuaLfQheVCiY6Xd9UtJc5A-2DVpGvwmVqsVBILkWHJ_f3d2ZZmA0xT6MqDj0zmaGc0J8CXhguWMlX5IJfepTkpf0KL0Uya0RB0TK26HTbDxmE-nYtI53JourXIpE62gLmqFPvIjG-HBoE78dXbn49QojK52IzQ2YAu7JMQ2dW-yri7SprivKniOfvYr90N6kGILGZ8_pJu2Z7IxT6x0oy4etkWtTjp_-b938wpedNYoOXbs8xqe6GoHno26ePsObDuvHnHFSm-gcim05KYiWHw2v8UiKaLkotENqUtSoEGJW11iOkEvL7n4fk2wioVgLwLS1gStAbJ_Ojwenh4MiSQ2qREn9c5bco8v38Kv87Orkwu_m9jgq4SJ1ucyjViqVI6_ujkXPC5QhEidi5RjgDCXrJCFjKNSs4IqUSaBWUNpmcZ5oKL4HWxWdaV3gQRcFFxTrrmhCZMiD1MZKWbQUisqPKDLd5Wprp05TtW4zdbkrYU0s6844x4c9rCZ6-fxGCBdMkK2LFY14jUzGucxIFsH1E0nJJoszJooCxwawUZpIdQgeY_s7CBn3_zLSQf3eLW_x4inxjCksQd7S4bMVhfSc6MHn_vNRs5g8EhWul7YfViC1h7z4L1j-tXBE-wkF9MPfz_4R3huGIyiZzwUe7DZzhf6EzxVv9ubZj6ADXZ5jXTKLOWG8pNwAFvfzsaTS7M0Chy9QhqNLP1h6WRgP_w_6f5LSQ
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1ba9RAFD6UKioUL_UWrXUEhfYhdpNMMjMLIsW17NLuIrhK38bJZAKFkl03WcU_5W90TibJUthaX_rgSx4m-Sa3c5s5N4DXMRcsZSz3A6q4T02c-4JmuZ8wYRTqmEjzutkEm0z46an4tAG_21wYDKtsZWItqLOZxj3yg9rDg06d6P38u49do9C72rbQcGRxbH79tEu28t1oYP_vmzA8-jj9MPSbrgK-jpmofK6SkCVap7gcS7ngUYZkrkwqEo5OrFSxTGUqCnPDMqpFHvfsCKV5EqU9jYUOrMi_gXX1MIRw3Juuy8OsQ-pXGUMHn7vBvYDuJ1iyxueX6cKtuSrtH8pda43Lbd9aBx7d-9--3n2421jb5NCxxwPYMMU23Bo38QTbsOV2LYlLxnoIhQsRJmcFweS6xTkmgRGtlqUpySwnGRrMeNYF3hPcxSbD0VeCWToEay2QakbQ2iF7g_5hf7DfJ4rUQZvYiXhRkQt89wi-XMvbP4bNYlaYp0B6XGTcUG64PcZMiTRIVKiZRSujqfCAtrQhdVOuHbuGnMs1cXkBlTVJSe7B2w42d_VKrgIkLeHJNhnXqg9pNepVQLYOaMpGCJYykGUoew6NYKuUEWqRvEM2dp6z3_7lprsXeKN7x5An1vClkQc7LQPI1YN01O_Bq-60laPoHFOFmS3ra1iM1izz4IljstXkMVbKi-izv0_-Em4Pp-MTeTKaHD-HO5bYKHoBArEDm9ViaV7ATf2jOisXu7XYIPDtujntD6OgnsA
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1ba9RAFD6UKkUoVetttdYRFNqHuJtkkplZECldly7VpeCFvk0nkwkUSrLdZBX_mr_OOZkkS2FrfemDL3lI9stlc26Zc75zAN5EXLCEsczzqeIeNVHmCZpmXsyEUehjQs3rYRNsOuWnp-JkDX63XBgsq2xtYm2o00LjGnm_zvBgUifsZ01ZxMlo_GF26eEEKcy0tuM0nIgcm18_7edb-X4ysu_6bRCMP349PPKaCQOejpioPK7igMVaJ_hplnDBwxRFXplExBwTWoliqUpVGGSGpVSLLBrYPZRmcZgMNDY9sOb_DgutFCNL_dBfxcmsy-uX7KH-l27nnk_3Y2xf4_Hr_OLmTJX2bWVuzMb1cXDtD8f3_-d_8gFsNVE4OXBq8xDWTL4NG5-bOoNt2HSrmcSRtB5B7kqHyXlOkHQ3v0ByGNFqUZqSFBlJMZDGo64gn-DqNjmafCfI3iHYg4FUBcEoiOyNhgfD0f6QKFIXc-KE4nlFrujjY_h2K0__BNbzIjfPgAy4SLmh3HC7jZgSiR-rQDOLVkZT0QPayonUTRt3nCZyIVfU6_lU1uIleQ_edbCZ62NyEyBuhVC2JF3rVqT1tDcB2SqgKRvjWEpfloEcODSCrbNGqEXyDtnEfy6u-5eL7l7Rk-4ZAx7bgJiGPdhplUEub6TThB687g5b-4pJM5WbYlH_hkUY5bIePHUKtzx5hB30Qvr87yd_BRtWweSnyfT4BdyzskYxOeCLHViv5gvzEu7qH9V5Od-tLQiBs9tWtD_htKc-
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Trends+in+underlying+causes+of+death+in+people+with+HIV+from+1999+to+2011+%28D%3AA%3AD%29%3A+a+multicohort+collaboration&rft.jtitle=The+Lancet+%28British+edition%29&rft.au=Smith%2C+Colette+J&rft.au=Ryom%2C+Lene&rft.au=Weber%2C+Rainer&rft.au=Morlat%2C+Philippe&rft.date=2014-07-19&rft.pub=Elsevier+Ltd&rft.issn=0140-6736&rft.volume=384&rft.issue=9939&rft.spage=241&rft.epage=248&rft_id=info:doi/10.1016%2FS0140-6736%2814%2960604-8&rft.externalDocID=S0140673614606048
thumbnail_m	http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01406736%2FS0140673614X60939%2Fcov150h.gif